CA2591781A1 - Method for biotransformation of the clyclosporin compound isa247 - Google Patents
Method for biotransformation of the clyclosporin compound isa247 Download PDFInfo
- Publication number
- CA2591781A1 CA2591781A1 CA002591781A CA2591781A CA2591781A1 CA 2591781 A1 CA2591781 A1 CA 2591781A1 CA 002591781 A CA002591781 A CA 002591781A CA 2591781 A CA2591781 A CA 2591781A CA 2591781 A1 CA2591781 A1 CA 2591781A1
- Authority
- CA
- Canada
- Prior art keywords
- isa247
- metabolites
- microorganism
- compound
- atcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 title claims abstract description 115
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 229960005289 voclosporin Drugs 0.000 title claims abstract description 73
- 108010057559 voclosporin Proteins 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 62
- 230000036983 biotransformation Effects 0.000 title claims abstract description 50
- 239000002207 metabolite Substances 0.000 claims abstract description 137
- 244000005700 microbiome Species 0.000 claims abstract description 72
- 239000004094 surface-active agent Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 239000002676 xenobiotic agent Substances 0.000 claims abstract description 33
- 230000002034 xenobiotic effect Effects 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- -1 cyclosporin compound Chemical class 0.000 claims description 46
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 34
- 102000004190 Enzymes Human genes 0.000 claims description 33
- 108090000790 Enzymes Proteins 0.000 claims description 33
- 108010036949 Cyclosporine Proteins 0.000 claims description 29
- 229930105110 Cyclosporin A Natural products 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 25
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000004359 castor oil Substances 0.000 claims description 18
- 235000019438 castor oil Nutrition 0.000 claims description 17
- 229960001265 ciclosporin Drugs 0.000 claims description 17
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 17
- 229930182912 cyclosporin Natural products 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 15
- 229920000136 polysorbate Polymers 0.000 claims description 14
- 241000187560 Saccharopolyspora Species 0.000 claims description 13
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 10
- 241000187712 Actinoplanes sp. Species 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 8
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 5
- 241001290628 Cunninghamella echinulata Species 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 5
- 241000187392 Streptomyces griseus Species 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 241001362614 Crassa Species 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 abstract description 6
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 230000016784 immunoglobulin production Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 28
- 229940079593 drug Drugs 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 12
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000813 microbial effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 229920001983 poloxamer Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 150000002009 diols Chemical class 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 125000005456 glyceride group Chemical group 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 108010036941 Cyclosporins Proteins 0.000 description 6
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 6
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 6
- 241000187559 Saccharopolyspora erythraea Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000010520 demethylation reaction Methods 0.000 description 6
- 239000012847 fine chemical Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001302652 Bassiana Species 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical class C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
- 235000015278 beef Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 210000001589 microsome Anatomy 0.000 description 5
- 229940049964 oleate Drugs 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 3
- AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000610620 Homo sapiens Putative serine protease 29 Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 101150053185 P450 gene Proteins 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 102100040345 Putative serine protease 29 Human genes 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940042006 metaproterenol sulfate Drugs 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 229960003556 aminophylline Drugs 0.000 description 2
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 229960002588 cefradine Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960001054 clorazepate dipotassium Drugs 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229960000648 digitoxin Drugs 0.000 description 2
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 229960003157 epinephrine bitartrate Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- 229960001751 fluoxymesterone Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960003404 mexiletine Drugs 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229960005105 terbutaline sulfate Drugs 0.000 description 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 description 2
- 229960000921 testosterone cypionate Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 description 1
- RSBLYYMNHJDITE-NBYYMMLRSA-N (1-hydroxy-1-phenylpropan-2-yl)-methyl-[(e)-3-phenylprop-2-enyl]azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1/C=C/C[NH+](C)C(C)C(O)C1=CC=CC=C1 RSBLYYMNHJDITE-NBYYMMLRSA-N 0.000 description 1
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 1
- LSBUIZREQYVRSY-CYJZLJNKSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrochloride Chemical compound Cl.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 LSBUIZREQYVRSY-CYJZLJNKSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- UBEIMDKGOYBUKT-FLIQGJDUSA-N 1,2,3-trilinolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC UBEIMDKGOYBUKT-FLIQGJDUSA-N 0.000 description 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XOZLRRYPUKAKMU-UHFFFAOYSA-N 1,5-dimethyl-2-phenyl-4-(propan-2-ylamino)-3-pyrazolone Chemical compound O=C1C(NC(C)C)=C(C)N(C)N1C1=CC=CC=C1 XOZLRRYPUKAKMU-UHFFFAOYSA-N 0.000 description 1
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SZLZWPPUNLXJEA-UHFFFAOYSA-N 11,17-dimethoxy-18-[3-(3,4,5-trimethoxy-phenyl)-acryloyloxy]-yohimbane-16-carboxylic acid methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C=CC1=CC(OC)=C(OC)C(OC)=C1 SZLZWPPUNLXJEA-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- ZZYHCCDMBJTROG-UHFFFAOYSA-N 2-(2-benzylphenoxy)ethyl-dimethylazanium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound OC(=O)CC(O)(C(O)=O)CC([O-])=O.C[NH+](C)CCOC1=CC=CC=C1CC1=CC=CC=C1 ZZYHCCDMBJTROG-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical compound CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-L 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfonatoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoate Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C([O-])=O)\C1=CSC(N)=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-L 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- NRSJYUSYBNFGAK-UHFFFAOYSA-N 3-bromo-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C=C1Br NRSJYUSYBNFGAK-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- NBUHTTJGQKIBMR-UHFFFAOYSA-N 4,6-dimethylpyrimidin-5-amine Chemical compound CC1=NC=NC(C)=C1N NBUHTTJGQKIBMR-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 description 1
- MUFDLGGSOCHQOC-HTKOBJQYSA-N 4-[(1s,2r)-1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol;hydrochloride Chemical compound Cl.CC(C)N[C@H](CC)[C@@H](O)C1=CC=C(O)C(O)=C1 MUFDLGGSOCHQOC-HTKOBJQYSA-N 0.000 description 1
- SOYAGMVKMXZVNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 SOYAGMVKMXZVNZ-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- JSXBVMKACNEMKY-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine;hydron;chloride Chemical compound Cl.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 JSXBVMKACNEMKY-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000187844 Actinoplanes Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- GTEBGKZZGCBLNT-RVWNTZLHSA-N CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 Chemical compound CC(O)=O.C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC)[C@H](C(C)=O)[C@@]1(C)CC2 GTEBGKZZGCBLNT-RVWNTZLHSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 241000222511 Coprinus Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- 241000223211 Curvularia lunata Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 101710128742 Cytochrome b6-f complex iron-sulfur subunit 2 Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- CVBMAZKKCSYWQR-BPJCFPRXSA-N Deserpidine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3 CVBMAZKKCSYWQR-BPJCFPRXSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- FGPGANCDNDLUST-CEGNMAFCSA-N Ethyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 FGPGANCDNDLUST-CEGNMAFCSA-N 0.000 description 1
- 239000001534 FEMA 4201 Substances 0.000 description 1
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- LRWSFOSWNAQHHW-UHFFFAOYSA-N Fluphenazine enanthate Chemical compound C1CN(CCOC(=O)CCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 LRWSFOSWNAQHHW-UHFFFAOYSA-N 0.000 description 1
- ZIIJJOPLRSCQNX-UHFFFAOYSA-N Flurazepam hydrochloride Chemical compound Cl.Cl.N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ZIIJJOPLRSCQNX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- MBXVIRZWSHICAV-UHFFFAOYSA-N Glycerol triundecanoate Chemical compound CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCC)COC(=O)CCCCCCCCCC MBXVIRZWSHICAV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000921533 Nonomuraea dietziae Species 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- RRJHESVQVSRQEX-SUYBPPKGSA-N O-formylcefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)C=3C=CC=CC=3)[C@H]2SC1 RRJHESVQVSRQEX-SUYBPPKGSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 241000204087 Pseudonocardia autotrophica Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- 244000061121 Rauvolfia serpentina Species 0.000 description 1
- SZLZWPPUNLXJEA-FMCDHCOASA-N Rescinnamine Natural products O=C(O[C@H]1[C@@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1 SZLZWPPUNLXJEA-FMCDHCOASA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000235546 Rhizopus stolonifer Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241001330507 Sebekia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 241001149679 [Candida] apicola Species 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940024223 alseroxylon Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229960005143 amobarbital sodium Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000151 anti-reflux effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- ZDQSOHOQTUFQEM-NURRSENYSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-NURRSENYSA-N 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003200 azlocillin sodium Drugs 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229960000585 bitolterol mesylate Drugs 0.000 description 1
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 229960004895 bretylium tosylate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- 229960003108 brompheniramine maleate Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004348 candicidin Drugs 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960000954 carbenicillin indanyl sodium Drugs 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- QFWPXOXWAUAYAB-XZVIDJSISA-M carindacillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 QFWPXOXWAUAYAB-XZVIDJSISA-M 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- 229960001065 cefadroxil monohydrate Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002440 cefamandole nafate Drugs 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- NAXFZVGOZUWLEP-RFXDPDBWSA-L cefonicid sodium Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS([O-])(=O)=O NAXFZVGOZUWLEP-RFXDPDBWSA-L 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960004445 cefotetan disodium Drugs 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960003016 cefoxitin sodium Drugs 0.000 description 1
- 229960000636 ceftizoxime sodium Drugs 0.000 description 1
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940084959 cephalexin hydrochloride Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229940009063 cephapirin sodium Drugs 0.000 description 1
- VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960001805 chloramphenicol palmitate Drugs 0.000 description 1
- PXKHGMGELZGJQE-ILBGXUMGSA-N chloramphenicol palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 PXKHGMGELZGJQE-ILBGXUMGSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- WEQAYVWKMWHEJO-UHFFFAOYSA-N chlormezanone Chemical compound O=S1(=O)CCC(=O)N(C)C1C1=CC=C(Cl)C=C1 WEQAYVWKMWHEJO-UHFFFAOYSA-N 0.000 description 1
- 229960002810 chlormezanone Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960002908 cimetidine hydrochloride Drugs 0.000 description 1
- 229960003833 cinnamedrine hydrochloride Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004714 clindamycin palmitate Drugs 0.000 description 1
- OYSKUZDIHNKWLV-PRUAPSLNSA-N clindamycin palmitate Chemical compound O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 OYSKUZDIHNKWLV-PRUAPSLNSA-N 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003026 cloxacillin sodium Drugs 0.000 description 1
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960004531 colistimethate sodium Drugs 0.000 description 1
- IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 description 1
- 229960001127 colistin sulfate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 1
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960001987 dantrolene Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- ISMCNVNDWFIXLM-WCGOZPBSSA-N deserpidine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ISMCNVNDWFIXLM-WCGOZPBSSA-N 0.000 description 1
- 229960001993 deserpidine Drugs 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 229960000559 dextrothyroxine sodium Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 1
- 229960005422 dichloralphenazone Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 229960002705 dihydrocodeine bitartrate Drugs 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229960001583 diphenhydramine citrate Drugs 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 1
- 229960001863 disopyramide phosphate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
- 229960001142 encainide Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940081345 estropipate Drugs 0.000 description 1
- HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960003670 flecainide acetate Drugs 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960000787 fluphenazine enanthate Drugs 0.000 description 1
- 229960003628 flurazepam hydrochloride Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- YUFWAVFNITUSHI-UHFFFAOYSA-N guanethidine monosulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.NC(=N)NCCN1CCCCCCC1 YUFWAVFNITUSHI-UHFFFAOYSA-N 0.000 description 1
- 229960002096 guanethidine monosulfate Drugs 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930182851 human metabolite Natural products 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960002764 hydrocodone bitartrate Drugs 0.000 description 1
- 229960003331 hydrocortisone cypionate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- 229960001560 hydroxyzine pamoate Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229940031585 isoetharine hydrochloride Drugs 0.000 description 1
- 229940038961 isoetharine mesylate Drugs 0.000 description 1
- 229960005409 isometheptene mucate Drugs 0.000 description 1
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical class O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960004990 loxapine hydrochloride Drugs 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000589 loxapine succinate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 229940051129 meperidine hydrochloride Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960002057 metharbital Drugs 0.000 description 1
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 description 1
- 229960004056 methdilazine Drugs 0.000 description 1
- 229940019826 methicillin sodium Drugs 0.000 description 1
- MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- 229940042053 methotrimeprazine Drugs 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 235000019508 mustard seed Nutrition 0.000 description 1
- WSXKZIDINJKWPM-IBGZLQDMSA-N n,6-dimethylhept-5-en-2-amine;(2s,3r,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound CNC(C)CCC=C(C)C.CNC(C)CCC=C(C)C.OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O WSXKZIDINJKWPM-IBGZLQDMSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- BCXCABRDBBWWGY-UHFFFAOYSA-N n-benzyl-n-methylprop-2-yn-1-amine;hydrochloride Chemical compound Cl.C#CCN(C)CC1=CC=CC=C1 BCXCABRDBBWWGY-UHFFFAOYSA-N 0.000 description 1
- XWESXZZECGOXDQ-UHFFFAOYSA-N n-tert-butylhydroxylamine Chemical compound CC(C)(C)NO XWESXZZECGOXDQ-UHFFFAOYSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- 229960001775 nafcillin sodium Drugs 0.000 description 1
- OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 description 1
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 description 1
- 229960001513 nalbuphine hydrochloride Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960003994 oxacillin sodium Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960003274 paramethadione Drugs 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- 229960004239 pargyline hydrochloride Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- 229940056362 penicillin g procaine Drugs 0.000 description 1
- 229940090663 penicillin v potassium Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002254 phenyltoloxamine citrate Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229960005264 piperacillin sodium Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 229940065347 propoxyphene hydrochloride Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 description 1
- 229960002454 quinidine gluconate Drugs 0.000 description 1
- 229960000755 quinidine polygalacturonate Drugs 0.000 description 1
- 239000009847 quinidine polygalacturonate Substances 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 229950000385 ramifenazone Drugs 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- SMSAPZICLFYVJS-QEGASFHISA-N rescinnamine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)\C=C\C1=CC(OC)=C(OC)C(OC)=C1 SMSAPZICLFYVJS-QEGASFHISA-N 0.000 description 1
- 229960001965 rescinnamine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- ANMYAHDLKVNJJO-CURYUGHLSA-M sodium;(2r)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;hydrate Chemical compound O.[Na+].IC1=CC(C[C@@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 ANMYAHDLKVNJJO-CURYUGHLSA-M 0.000 description 1
- VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- YUSMZDVTEOAHDL-NTMALXAHSA-N tert-butyl (3z)-3-(dimethylaminomethylidene)-4-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CN(C(=O)OC(C)(C)C)CCC1=O YUSMZDVTEOAHDL-NTMALXAHSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 229960004869 thiethylperazine Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 1
- 229960004098 thioridazine hydrochloride Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229960004075 ticarcillin disodium Drugs 0.000 description 1
- ZBBCUBMBMZNEME-QBGWIPKPSA-L ticarcillin disodium Chemical compound [Na+].[Na+].C=1([C@@H](C([O-])=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)C=CSC=1 ZBBCUBMBMZNEME-QBGWIPKPSA-L 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229950011638 traxanox Drugs 0.000 description 1
- MLCGWPUVZKTVLO-UHFFFAOYSA-N traxanox Chemical compound C=1C(C(C2=CC=CN=C2O2)=O)=C2C(Cl)=CC=1C=1N=NNN=1 MLCGWPUVZKTVLO-UHFFFAOYSA-N 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 description 1
- 229940035742 trimethaphan Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960001572 vancomycin hydrochloride Drugs 0.000 description 1
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
- C12P35/06—Cephalosporin C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of producing metabolites of a xenobiotic compound by biotransformation using a microorganism, wherein the xenobiotic compound is cyclosprorm ISA247, which is delivered to the microorganism in a mixture with a surfactant The method can be scaled up to produce large quantities of metabolites by, for example, biotransformation in a reactor The metabolites produced by the present method can be used for antibody production, as standards in therapeutic dose monitoring, or in pharmaceutical applications
Description
METHODS FOR THE BIOTRANSFORMATION OF THE CLYCLOSPORIN COMPOUND ISA247.
TECHNICAL FIELD
[0001] This invention relates to methods of preparing metabolites of compounds, and more particularly to the preparation of such metabolites by biotransformation.
BACKGROUND
TECHNICAL FIELD
[0001] This invention relates to methods of preparing metabolites of compounds, and more particularly to the preparation of such metabolites by biotransformation.
BACKGROUND
[0002] When dosing a patient with a pharmaceutical compound, it is often necessary to monitor the serum levels of the drug to ensure that the patient is receiving a therapeutic dose of the drug.
This is called therapeutic dose monitoring (TDM). TDM may measure the parent compound and/or one or more metabolites of the parent compound. Metabolites are formed when enzymes, commonly liver enzymes, work to break down or modify a drug so that the drug can be more easily eliminated from the body. When the parent compound is rapidly metabolized, it may be most convenient to measure the levels of a metabolite for the purposes of TDM.
Frequently, immunoassays are used for such measurements.
This is called therapeutic dose monitoring (TDM). TDM may measure the parent compound and/or one or more metabolites of the parent compound. Metabolites are formed when enzymes, commonly liver enzymes, work to break down or modify a drug so that the drug can be more easily eliminated from the body. When the parent compound is rapidly metabolized, it may be most convenient to measure the levels of a metabolite for the purposes of TDM.
Frequently, immunoassays are used for such measurements.
[0003] When a TDM assay for measuring a metabolite is an immunoassay, the drug, or an isolated, purified metabolite of the drug, may be used for generating andlor selecting for an antibody having the desired specificity for use in that assay. Alternatively, the purified metabolite may be used to define an antibody specific for the parent coinpound, i.e., an antibody that exhibits minimal cross-reactivity between the parent compound and metabolites of the parent compound. Therefore, efficient methods for producing isolated metabolites are needed in order to obtain a quantity of metabolite suitable for use in producing antibodies for TDM.
20, [0004] Metabolites may also have uses that are independent of TDM.
Metabolites may have pharmaceutically important activities. For example, metabolites may exhibit beneficial characteristics such as improved pharmacokinetics, increased pharmacological activity or improved bioavailability. A metabolite of a parent drug compound may itself be a useful therapeutic. For example, A77 1726 is the active metabolite of leflunomide;
hydroxy-tert-butylamide is the active metabolite of the HIV drug, nelfmavir; and 4-OH-tamoxifen is the active metabolite of tamoxifen. When the metabolite exhibits activity, efficient methods of producing large quantities of the metabolite may be desired. Alternatively, one or more of the metabolites may be toxic. Thus, knowledge about how a drug is metabolized, its resulting metabolites, and the activity of these metabolites is important for understanding the activity of a drug. This information may also be required prior to drug approval. In order to identify the metabolites and their properties, a sufficient quantity of the metabolites must be produced and isolated.
[0005] One method for producing metabolites is to administer the drug to a mammal, such as a human, then collect blood, urine, bile or other body fluids, and extract, purify, and isolate metabolites from these fluids. Commonly, biotransformation, the conversion of a drug to metabolites of the drug, is achieved in human patients in the liver by the liver cytochrome P450 enzymes (CYP450 or P450). The P450 enyzme family includes an estimated 70 or so enzymes which act to render a compound more soluble for excretion in the bile or urine. To monitor metabolite formation by biotransforination, a parent compound may be tagged so that the metabolites may be recognized. Alternatively, a drug having a similar structure may be analyzed in parallel when the results are monitored by high pressure liquid chromatography separation and mass spectral analysis. A second method for biotransformation of a parent compound is to use a whole organ, a tissue slice, or cultured cells such as hepatocytes as a biotransforming system. In a third method, microsomes prepared from mammalian cells may be used. These approaches use animal isolates, thus risking introduction of unwanted contaminants into the metabolites. These methods are difficult to scale up when larger quantities of one or more of the metabolites is desired. In addition, biotransformations using microorganisms to convert the parent compound into metabolites may also be used.
[0006] It may be particularly difficult to produce large quantities of metabolites when the xenobiotic agent is highly lipophilic or highly insoluble in the aqueous media used in large scale fermentation methods. Therefore, a method for efficiently producing large quantities of metabolites of insoluble xenobiotics is needed.
SUIVIlVIARY
[0007] The present inverition provides methods of producing metabolites of xenobiotic compounds by biotransformation using a microorganism. The xenobiotic compound may be delivered to the microorganism in a mixture with a surfactant. The method can be scaled up to produce large quantities of metabolites by, for example, biotransformation in a reactor. The metabolites produced by the present method can be used, for example, for antibody production, as standards in therapeutic dose monitoring, or in pha.nnaceutical applications.
[0008] Accordingly, one aspect of the present invention provides a method for producing at least one metabolite of a xenobiotic compound in a microorganism, comprising the steps of:
(a) providing a mixture of the xenobiotic coinpound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and (c) incubating the culture for a period of time sufficient to allow the metabolite to fonn.
[0009] The mixture may comprise the xenobiotic compound, a solvent, and the surfactant.
Any suitable solvent for the xenobiotic compound can be used. For example, the solvent may an alcohol, such as ethanol. The solvents may comprise more than one substance.
In some embodiments, the solvent comprises both an alcohol and dimetheyl sulfoxide (DMSO).
[0010] The microorganism may be any microorganism that is capable of metabolizing the xenobiotic compound, preferably one that possesses the same metabolizing pathway for the xenobiotic coinpound as the human does. In certain embodiments, the microorganism is selected from the group consisting of Actinoplanes sp., Streptoynyces griseus, Streptomyces setonii, and Saccharopolyspora erthyraea. The microorganism may also be Cunningham ellaechinulata, Nerospora crassa, or Actinoplanes sp.
[0011] The surfactant may be any suitable surfactant, wliich can be identified by a skilled artisan based on teachirigs of the present disclosure. For example, the surfactant may be selected from the group consisting of polyethylene glycol (PEG) 400, castor oil, isopropyl myristate, glycerine, Cremophor0 (polyoxyl castor oil), Labrasol0 (caprylocaproyl macrogolglycerides), and TWEENO 40.
[0012] The xenobiotic compound is preferably a compound with a low solubility in aqueous solutions. In some einbodiments, the xenobiotic compound is selected from the group consisting of immunosuppressants and anti-bacterial compounds, preferably a cyclosporin compound, more preferably ISA247 or cyclosporin A. The metabolite is preferably selected from the group consisting of IM1-d-1, IMI-d-2, IMI-d-3, IMI-d-4, IM1-c-1, IM1-c-2, IMl-e-1, IM1-e-2, IM1-e-3, IM9, IM4, IM4n, IM6, IIVI46, IM69, and IM49.
[0013] The method of the present invention may optionally further comprise the step of isolating the metabolite from the culture.
[00141 Another aspect of the present invention provides a method for identifying a microorganism suitable for use in a biotransformation system comprising: a) comparing the structure of a compound to be metabolized with a known enzyme activity; b) identifying an enzyme that expresses the known enzyme activity; c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyme in a biotransformation system to make metabolites of the compound. In certain embodiments, the microorganism may be identified by comparing the genomic sequence of various microorganisms to the sequence of the identified enzyme, thereby identifying at least one microorganism that expresses the enzyme.
[0015] The details of one or more embodiments of the invention are set forth in the accompa-nying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS
[0016] Figure 1 illustrates the structure of ISA247. The amino acid residues in ISA247 are indicated by numbers. Greek letters indicate the carbon positions of amino acid 1.
[0017] Figures 2A and 2B provide the structures of the trans (E-) and cis (Z-) isomers of ISA247 molecule, respectively.
[0018] Figure 3 is an HPLC scan showing the profile of the ISA247 metabolites isolated from human whole blood of a subject who had received a 50:50 mixture of cis:trans ISA247.
[0019] Figure 4 is an HPLC scan illustrating the profile of the ISA247 metabolites isolated from the biotransformation method described in Example 4.
20, [0004] Metabolites may also have uses that are independent of TDM.
Metabolites may have pharmaceutically important activities. For example, metabolites may exhibit beneficial characteristics such as improved pharmacokinetics, increased pharmacological activity or improved bioavailability. A metabolite of a parent drug compound may itself be a useful therapeutic. For example, A77 1726 is the active metabolite of leflunomide;
hydroxy-tert-butylamide is the active metabolite of the HIV drug, nelfmavir; and 4-OH-tamoxifen is the active metabolite of tamoxifen. When the metabolite exhibits activity, efficient methods of producing large quantities of the metabolite may be desired. Alternatively, one or more of the metabolites may be toxic. Thus, knowledge about how a drug is metabolized, its resulting metabolites, and the activity of these metabolites is important for understanding the activity of a drug. This information may also be required prior to drug approval. In order to identify the metabolites and their properties, a sufficient quantity of the metabolites must be produced and isolated.
[0005] One method for producing metabolites is to administer the drug to a mammal, such as a human, then collect blood, urine, bile or other body fluids, and extract, purify, and isolate metabolites from these fluids. Commonly, biotransformation, the conversion of a drug to metabolites of the drug, is achieved in human patients in the liver by the liver cytochrome P450 enzymes (CYP450 or P450). The P450 enyzme family includes an estimated 70 or so enzymes which act to render a compound more soluble for excretion in the bile or urine. To monitor metabolite formation by biotransforination, a parent compound may be tagged so that the metabolites may be recognized. Alternatively, a drug having a similar structure may be analyzed in parallel when the results are monitored by high pressure liquid chromatography separation and mass spectral analysis. A second method for biotransformation of a parent compound is to use a whole organ, a tissue slice, or cultured cells such as hepatocytes as a biotransforming system. In a third method, microsomes prepared from mammalian cells may be used. These approaches use animal isolates, thus risking introduction of unwanted contaminants into the metabolites. These methods are difficult to scale up when larger quantities of one or more of the metabolites is desired. In addition, biotransformations using microorganisms to convert the parent compound into metabolites may also be used.
[0006] It may be particularly difficult to produce large quantities of metabolites when the xenobiotic agent is highly lipophilic or highly insoluble in the aqueous media used in large scale fermentation methods. Therefore, a method for efficiently producing large quantities of metabolites of insoluble xenobiotics is needed.
SUIVIlVIARY
[0007] The present inverition provides methods of producing metabolites of xenobiotic compounds by biotransformation using a microorganism. The xenobiotic compound may be delivered to the microorganism in a mixture with a surfactant. The method can be scaled up to produce large quantities of metabolites by, for example, biotransformation in a reactor. The metabolites produced by the present method can be used, for example, for antibody production, as standards in therapeutic dose monitoring, or in pha.nnaceutical applications.
[0008] Accordingly, one aspect of the present invention provides a method for producing at least one metabolite of a xenobiotic compound in a microorganism, comprising the steps of:
(a) providing a mixture of the xenobiotic coinpound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and (c) incubating the culture for a period of time sufficient to allow the metabolite to fonn.
[0009] The mixture may comprise the xenobiotic compound, a solvent, and the surfactant.
Any suitable solvent for the xenobiotic compound can be used. For example, the solvent may an alcohol, such as ethanol. The solvents may comprise more than one substance.
In some embodiments, the solvent comprises both an alcohol and dimetheyl sulfoxide (DMSO).
[0010] The microorganism may be any microorganism that is capable of metabolizing the xenobiotic compound, preferably one that possesses the same metabolizing pathway for the xenobiotic coinpound as the human does. In certain embodiments, the microorganism is selected from the group consisting of Actinoplanes sp., Streptoynyces griseus, Streptomyces setonii, and Saccharopolyspora erthyraea. The microorganism may also be Cunningham ellaechinulata, Nerospora crassa, or Actinoplanes sp.
[0011] The surfactant may be any suitable surfactant, wliich can be identified by a skilled artisan based on teachirigs of the present disclosure. For example, the surfactant may be selected from the group consisting of polyethylene glycol (PEG) 400, castor oil, isopropyl myristate, glycerine, Cremophor0 (polyoxyl castor oil), Labrasol0 (caprylocaproyl macrogolglycerides), and TWEENO 40.
[0012] The xenobiotic compound is preferably a compound with a low solubility in aqueous solutions. In some einbodiments, the xenobiotic compound is selected from the group consisting of immunosuppressants and anti-bacterial compounds, preferably a cyclosporin compound, more preferably ISA247 or cyclosporin A. The metabolite is preferably selected from the group consisting of IM1-d-1, IMI-d-2, IMI-d-3, IMI-d-4, IM1-c-1, IM1-c-2, IMl-e-1, IM1-e-2, IM1-e-3, IM9, IM4, IM4n, IM6, IIVI46, IM69, and IM49.
[0013] The method of the present invention may optionally further comprise the step of isolating the metabolite from the culture.
[00141 Another aspect of the present invention provides a method for identifying a microorganism suitable for use in a biotransformation system comprising: a) comparing the structure of a compound to be metabolized with a known enzyme activity; b) identifying an enzyme that expresses the known enzyme activity; c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyme in a biotransformation system to make metabolites of the compound. In certain embodiments, the microorganism may be identified by comparing the genomic sequence of various microorganisms to the sequence of the identified enzyme, thereby identifying at least one microorganism that expresses the enzyme.
[0015] The details of one or more embodiments of the invention are set forth in the accompa-nying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS
[0016] Figure 1 illustrates the structure of ISA247. The amino acid residues in ISA247 are indicated by numbers. Greek letters indicate the carbon positions of amino acid 1.
[0017] Figures 2A and 2B provide the structures of the trans (E-) and cis (Z-) isomers of ISA247 molecule, respectively.
[0018] Figure 3 is an HPLC scan showing the profile of the ISA247 metabolites isolated from human whole blood of a subject who had received a 50:50 mixture of cis:trans ISA247.
[0019] Figure 4 is an HPLC scan illustrating the profile of the ISA247 metabolites isolated from the biotransformation method described in Example 4.
[0020] Figure 5 is a graph showing the effects on ISA247 metabolite production of different surfactants in a biotransformation system.
[0021] Figure 6 shows the LC-MS profile of the ISA247 metabolites isolated from human whole blood of a subject who had received an ISA247 formulation that contained predominantly the trans-isomer of ISA247.
[0022] Figures 7 and 8 compare the effects of Media 3 and Media 16 on ISA247 metabolite production by Actinoplanes sp. (ATCC 53771) and Saccharopolyspora erythraea (ATCC
11635), respectively.
[0023] Figure 9 demonstrates the effects of different solvents and surfactants on ISA247 metabolite production by BeaztvaYia bassiana.
DETAILED DESCRIPTION.
[0024] The present invention provides methods of producing metabolites of xenobiotic compounds by biotransforrnation using a microorganism. Specifically, the xenobiotic compound is delivered to the microorganism in a mixture with a surfactant. The method can be scaled up to produce large quantities of metabolites by, for example, biotransformation in a reactor. The metabolites produced by the present method can be used, for example, for antibody production, as standards in therapeutic dose monitoring, or in pharmaceutical applications.
[0025] Many pharmaceutically active compounds are poorly soluble in aqueous solutions. For example, cyclosporins and certain other immunosuppressive agents (rapamycin, azathioprine, mizoribine, and FK506 (tacrolimus)) are known to exhibit poor solubility in an aqueous environment. Using a cyclosporin derivative; ISA247, as a test compound, we discovered that microbial fermentation can be successfully used to prepare inetabolites of poorly soluble compounds. Prior to describing the invention in further detail, the terms used in this application are defined as follows unless otherwise indicated.
[0021] Figure 6 shows the LC-MS profile of the ISA247 metabolites isolated from human whole blood of a subject who had received an ISA247 formulation that contained predominantly the trans-isomer of ISA247.
[0022] Figures 7 and 8 compare the effects of Media 3 and Media 16 on ISA247 metabolite production by Actinoplanes sp. (ATCC 53771) and Saccharopolyspora erythraea (ATCC
11635), respectively.
[0023] Figure 9 demonstrates the effects of different solvents and surfactants on ISA247 metabolite production by BeaztvaYia bassiana.
DETAILED DESCRIPTION.
[0024] The present invention provides methods of producing metabolites of xenobiotic compounds by biotransforrnation using a microorganism. Specifically, the xenobiotic compound is delivered to the microorganism in a mixture with a surfactant. The method can be scaled up to produce large quantities of metabolites by, for example, biotransformation in a reactor. The metabolites produced by the present method can be used, for example, for antibody production, as standards in therapeutic dose monitoring, or in pharmaceutical applications.
[0025] Many pharmaceutically active compounds are poorly soluble in aqueous solutions. For example, cyclosporins and certain other immunosuppressive agents (rapamycin, azathioprine, mizoribine, and FK506 (tacrolimus)) are known to exhibit poor solubility in an aqueous environment. Using a cyclosporin derivative; ISA247, as a test compound, we discovered that microbial fermentation can be successfully used to prepare inetabolites of poorly soluble compounds. Prior to describing the invention in further detail, the terms used in this application are defined as follows unless otherwise indicated.
Definition [0026] The term "biotransformation," as used herein, refers to the process of metabolizing a compound by a living cell, particularly a cell of a microorganism.
[0027] A "xenobiotic compound," or "xenobiotic," is a compound that is not native with respect to a microorganism. A xenobiotic compound may be pharmaceutically active. The xenobiotic compounds of this invention are preferably not readily soluble in water. For example, the compound may have a water solubility, at 25 C, of 1 mg/ml or less, 0.75 mg/ml or less, 0.5 mg/ml or less, 0.25 mg/ml or less, 0.1 mg/ml or less, 0.08 mg/ml or less, 0.06 mg/ml or less, 0.04 mg/ml or less, or 0.02 mg/ml or less.
[0028] A "cyclosporin compound" is a cyclosporin, or derivative thereof, that has immunosuppressive activities. The term encompasses the naturally occurring cyclosporins, cyclosporin A to Z, ISA247, synthetic and artificial dihydro- and iso-cyclosporins such as those disclosed in US Pat. Nos. 4,108,985; 4,210,581 and 4,220,641; derivatized cyclosporins such as shown in US Pat. Nos. 4,384,996; 4,703,033; 4,764,503; 4,771,122; 4,798,823;
4,885,276;
5,525,590; 5,643,870; 5,767,069; and cyclosporine derivative compounds as provided in W002069902; W003033010; W003030834; and W004050687.
ISA247 and its metabolites [0029] ISA247 (ISATX247 or ISA) and its ISA related family members are illustrated in US
Pat. Nos. 6,613,739 and 6,605,593. Like cyclosporin A, ISA247 is a cyclic undecapeptide 2o consisting almost entirely of hydrophobic amino acids. Many of these amino acids are not normally found in mainmalian proteins. Figure 1 illustrates the structure of ISA247 and the 11 amino acid residues that comprise the cyclic peptide ring of this molecule. As shown, the amino acid residues are numbered in a clockwise direction. As shown in Figure 1, seven amino acids of the eleven amino acids of the 11-membered amino acid ring are N-methylated.
The four remaining protonated nitrogen atoms can form intermolecular hydrogen bonds with carbonyl groups, which contribute substantially to the rigidity of the cyclosporin skeleton for both CsA
and ISA247. CsA has a solubility of about 0.04 mg/ml at 25 C. Due to its low water-solubility, the bioavailability of cyclosporin A is known to be 30% or less when orally administered to humans. ISA247 exhibits a similarly low water solubility.
[0030] ISA247 contains a sarcosine residue (whose three letter abbreviation is Sar; sarcosine is a methylated glycine residue and may also be abbreviated MeGly), one each of a D- and an L-alanine (Ala) residue, an a-amino butyric acid residue (Abu), a valine (Val) residue, an N-methyl valine (MeVal) residue, four N-methyl leucine (MeLeu) residues, and an alkene-containing 9-carbon, (3-hydroxylated amino acid unique to the cyclosporins called (4R)-4-[(E)-2-butenyl]-4,N-dimethyl-L-threonine (MeBmt). The chemical name of ISA247 is cyclo {{(E)- and (Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonodienoyl} -L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}. Its empirical formula is C63H111N11012.I. It has a molecular weight of about 1214.85.
[0031] ISA247 is known to exist in two isomeric forms, cis-ISA247 (or Z-ISA247) and trans-ISA247 (or E-ISA247). Figures 2A and 2B illustrates the trans and cis forms of ISA247. A
mixture of cis and tr-ans forms of the ISA247 compound has been found to be less toxic and more potent than CsA (See U.S. Pat. Nos. 6,605,593 and 6,613,739). In addition, ISA247 has been found to be less toxic and more potent than CsA as a mixture of cis and trans fonns when the mixture contains a predominant proportion of the trans isomer. When referring to ISA247, it will be understood by those of skill in the art that ISA247 is a mixture of the cis and trans isomers, and that the mixture may be enriched in the trans isomeric form of the compound. The isomeric compounds may be present in a mixture, ranging from 1:99 cis:trans to 99:1 cis: trans.
[0027] A "xenobiotic compound," or "xenobiotic," is a compound that is not native with respect to a microorganism. A xenobiotic compound may be pharmaceutically active. The xenobiotic compounds of this invention are preferably not readily soluble in water. For example, the compound may have a water solubility, at 25 C, of 1 mg/ml or less, 0.75 mg/ml or less, 0.5 mg/ml or less, 0.25 mg/ml or less, 0.1 mg/ml or less, 0.08 mg/ml or less, 0.06 mg/ml or less, 0.04 mg/ml or less, or 0.02 mg/ml or less.
[0028] A "cyclosporin compound" is a cyclosporin, or derivative thereof, that has immunosuppressive activities. The term encompasses the naturally occurring cyclosporins, cyclosporin A to Z, ISA247, synthetic and artificial dihydro- and iso-cyclosporins such as those disclosed in US Pat. Nos. 4,108,985; 4,210,581 and 4,220,641; derivatized cyclosporins such as shown in US Pat. Nos. 4,384,996; 4,703,033; 4,764,503; 4,771,122; 4,798,823;
4,885,276;
5,525,590; 5,643,870; 5,767,069; and cyclosporine derivative compounds as provided in W002069902; W003033010; W003030834; and W004050687.
ISA247 and its metabolites [0029] ISA247 (ISATX247 or ISA) and its ISA related family members are illustrated in US
Pat. Nos. 6,613,739 and 6,605,593. Like cyclosporin A, ISA247 is a cyclic undecapeptide 2o consisting almost entirely of hydrophobic amino acids. Many of these amino acids are not normally found in mainmalian proteins. Figure 1 illustrates the structure of ISA247 and the 11 amino acid residues that comprise the cyclic peptide ring of this molecule. As shown, the amino acid residues are numbered in a clockwise direction. As shown in Figure 1, seven amino acids of the eleven amino acids of the 11-membered amino acid ring are N-methylated.
The four remaining protonated nitrogen atoms can form intermolecular hydrogen bonds with carbonyl groups, which contribute substantially to the rigidity of the cyclosporin skeleton for both CsA
and ISA247. CsA has a solubility of about 0.04 mg/ml at 25 C. Due to its low water-solubility, the bioavailability of cyclosporin A is known to be 30% or less when orally administered to humans. ISA247 exhibits a similarly low water solubility.
[0030] ISA247 contains a sarcosine residue (whose three letter abbreviation is Sar; sarcosine is a methylated glycine residue and may also be abbreviated MeGly), one each of a D- and an L-alanine (Ala) residue, an a-amino butyric acid residue (Abu), a valine (Val) residue, an N-methyl valine (MeVal) residue, four N-methyl leucine (MeLeu) residues, and an alkene-containing 9-carbon, (3-hydroxylated amino acid unique to the cyclosporins called (4R)-4-[(E)-2-butenyl]-4,N-dimethyl-L-threonine (MeBmt). The chemical name of ISA247 is cyclo {{(E)- and (Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonodienoyl} -L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}. Its empirical formula is C63H111N11012.I. It has a molecular weight of about 1214.85.
[0031] ISA247 is known to exist in two isomeric forms, cis-ISA247 (or Z-ISA247) and trans-ISA247 (or E-ISA247). Figures 2A and 2B illustrates the trans and cis forms of ISA247. A
mixture of cis and tr-ans forms of the ISA247 compound has been found to be less toxic and more potent than CsA (See U.S. Pat. Nos. 6,605,593 and 6,613,739). In addition, ISA247 has been found to be less toxic and more potent than CsA as a mixture of cis and trans fonns when the mixture contains a predominant proportion of the trans isomer. When referring to ISA247, it will be understood by those of skill in the art that ISA247 is a mixture of the cis and trans isomers, and that the mixture may be enriched in the trans isomeric form of the compound. The isomeric compounds may be present in a mixture, ranging from 1:99 cis:trans to 99:1 cis: trans.
[0032] ISA247 metabolites can be described as follows: A compound of formula 1:
R3 RZ R4 RZ R' CH2 R2 RZ-N=C C-N-C-C-N-C-C-N-C-C-N CH2 CO
R3-cv I 2 (I) -N
OC-C ' N-C-C? N-C-C6 N-C-CS N-C 4-ICH
CH H 0 CH H O R3 Ry 0 R4 H 0 R3 wherein Rl is selected from the group consisting of:
0 0 I ro HO
HO HO HO HO
HO HON'' I
HO HO~~
OH OH
I OH ~ OH
HO
I OH ~OH OH LOH
HO HOX\ HO\~ HO
HO, HO ~
' OH
~- .
O
O
R3 RZ R4 RZ R' CH2 R2 RZ-N=C C-N-C-C-N-C-C-N-C-C-N CH2 CO
R3-cv I 2 (I) -N
OC-C ' N-C-C? N-C-C6 N-C-CS N-C 4-ICH
CH H 0 CH H O R3 Ry 0 R4 H 0 R3 wherein Rl is selected from the group consisting of:
0 0 I ro HO
HO HO HO HO
HO HON'' I
HO HO~~
OH OH
I OH ~ OH
HO
I OH ~OH OH LOH
HO HOX\ HO\~ HO
HO, HO ~
' OH
~- .
O
O
HO OH HO
> and Where R2 is selected from the group consisting of CH3 and H; where R3)is selected from the group consisting of CH2CH(CH3)2 and CH2C(CH3)20H; and where R4 is selected from the group consisting of CH(CH3)2 and C(CH3)20H.
[0034] Structures of ISA247 metabolites which are modifications at amino acid-1 of the ISA247 compound are illustrated in Table 1. The boxes represent amino acids 2-11 which form the ring portion of the cyclosporin structure with the modified amino acid-l, see Figure 1. Table 1 is not an exhaustive list of ISA247 metabolites that are modified at amino acid-1. For example, amino acid 1 metabolites may include 5, 6, 7 or 8 member rings.
Table 1: Amino Acid 1 Metabolites of ISA
IM1-e-1 CH CH
I91 -e-1 IMl-e-1 IM1-e-2 HO
CH
IM 1-e-2 IM1-e-3 O
HO
CH
IM 1-e-3 IM1-d-1 OH H
H/' HO
+
HO HO
IM1Hd-1 IM1 d1 TM 1 -d-2 HO HO
, HopO~' Ho H HO
cH~ CH~
IMI-J-? IMI-J-?
IM 1-d-3 OH OH
OH OH HO HO
CH3 CH, IMl d-3 IM1Hd-3 IMl-d-4 I OH I OH I OH onIIOH
HO HO
H CH Ho OH' HO CH~ Ho CH~
IMIHJ-4 IMI-J=A IMICJ-4 IMI-J-4 -_, IMl-c-1 H H
O
CH~ 9--F-ICHIMI-ul IM1-c-2 OH
O
CHa HO
HO OH
COzH
HO
[0035] ISA247 metabolites include N-demethylated metabolites where the N-demethylation occurs at at least one methylated nitrogen of the amide linkage of an alnino acid, for example, IM4n, (or ISA247 Metabolite, N-demethylation at amino acid-4). N-demethylation can occur at amino acid-3 (IM3n), amino acid=4 (IM4n), amino acid-6 (IM6n), amino acid-9 (IM9n), amino acid- 10 (IM10n) or ainino acid-11 (IM 11 n). ISA247 metabolites also include hydroxylated metabolites where the hydroxylation occurs at at least one methyl leucine amino acid, for example amino acids 4, 6, 9 or 10 (IM4, IM6, IM9 or IM10), or at valine residue 5(IM5) or at methyl valine residue 11 (IMl 1). IM46 are hydroxylated at both ainino acids 4 and 6, IM49 are hydroxylated at both amino acids 4 and 9, and so on. Combinations of N-demethylated and hydroxylated metabolites can occur, as well as combinations of the metabolites which are alterations at amino acid-1, as shown in Table 1, with N-demethylations or hydroxylations.
ISA247 nzetabolites also include metabolites which are glucuronide, sulfonide, glycosylated and phosphorylated derivatives of hydroxylated metabolites of ISA247. U.S. Pat.
Application No.
_(Attorney Docket Number 16593-009001, filed December 19, 2005) co-pending and commonly assigned to the assignee provides ISA247 metabolites and uses thereof.
Methods of preparing ISA247 metabolites [0036] Metabolites of ISA247 were first analyzed using human whole blood of a subject who had received a 50:50 mixture of cis:trans ISA247 (Example 1). Figure 3 is an HPLC scan illustrating the metabolite profile of metabolites isolated from the whole blood of this subject.
Using organic extractions on human whole blood, metabolites were extracted, dried, reconstituted in methanol and identified using chromatographic techniques coupled with mass spectrometry. As shown in Figure 3, at least three diol , two hydroxylated and three N-demethylated metabolites were detectable in human whole blood.
[0037] A dog liver microsome preparation was also used to produce 1SA247 metabolites (Example 2). While ISA247 metabolites can be produced in this manner, the yield was low and the cost was high. Therefore, it is not practical to obtain meaningful quantities of ISA247 metabolites using this approach.
[0038] To our knowledge, prior to the present invention, conventional biotransformation methods had not been reported as producing quantities of metabolites of CsA
and ISA247, perhaps because of the lipophilic nature of these compounds. Without wislung to be bound by any theory, we believe the problem is that a hydrophobic compound, such as ISA247, has a tendency to adhere to the surfaces of filters, columns, and other hardware used to carry out the culture and process the product metabolites. Also, these highly lipophilic coinpounds do not go into solution in the aqueous environment of microorganisms in culture.
Cultured microorganisms may not be able to access these lipophilic compounds to metabolize them. In some aspects, providing drug to a microbial growth preparation is not unlike providing drug to a mammal. A formulation that increases the bioavailability of the drug may be necessary.
[0039] In humans, cytochrome P450 enzymes are known to fonn metabolites from CsA. It has been found that cytochrome P450 enzymes also act to form ISA247 metabolites.
Specifically, the cytochrome P450 enzyine CYP3A4 has been identified as the enzyme responsible for cyclosporin and ISA247 metabolism. In order to produce a metabolite profile that is similar to that obtained from humans, the biotransformation system must utilize a microorganism which has the microbial equivalent of the human cytochrome P450 enzyme, grown in a medium and under culture conditions suitable for active growth and metabolism of the microorganism.
[0040] Biotransformation methods are exemplified in Smith et al. (Arch.
Biochem. Biophys.
(1974) 161: 551-558). Urlacker and Schmid (Curr Opin Biotechnol. (2002) 13(6):557-64) suggest that biotransformations could be performed using prokaryotic P450 monooxygenase enzymes. Venisetty andCiddi (Current Pharmaceutical Biotechnology (2003) 4(3):153-167) have proposed application of microorganisms to natural drugs to find novel drugs.
[0041] Biotransformation of cyclosporin A solubilized in methanol by Sebekia beraihana to [y-hydroxy-MeLeu]4 cyclosporin (AM4) and to [,y-hydroxy-MeLeu]4 [y-hydroxy-MeLeu]6 cyclosporin (AM46) has been disclosed in US Pat. No. 6,255,100. However, it should be noted that when CsA is administered to a human, the predominate metabolites that are produced and monitored for TDM are AM 1 (a metabolite of CsA that is hydroxylated at amino acid-l, MeBmt), AM9 (a metabolite that is hydroxylated at the MeLeu at amino acid position 9) and AM4n (a metabolite of CsA that is demethylated at the Meleu at amino acid position 4) (LeGatt et al., Clin Biochem. (1994) 27(1):43-8). Thus, Sebekia benihana exemplifies a microorganism that does not provide a metabolic profile that mimics the mainmalian metabolic profile of CsA.
[0042] We demonstrate herein that biotransformation can be used to produce metabolites of ISA247. As shown in Example 3, by delivering a mixture containing ISA247 and the surfactant TWEENO 40 (polyoxyethylene sorbitan monopalmitate) to Saccharopolyspora erytlzey-aea, all the main categories of ISA247 metabolites found in human blood were produced.
Specifically, seven ISA247 metabolites were detected: IM4n (ISA247 Metabolite that is N-demethylated at amino acid-4), IM9 (ISA247 Metabolite that is hydroxylated at amino acid-9), IM4 (ISA247 Metabolite that is hydroxylated at amino acid-4), IM1-c-1(See table 1), IM1-d-1 (Table 1), IMl-d-2 (Table 1) and IMl-d-3 (Table 1). Different microorganisms produce different types, numbers and quantities of ISA247 metabolites, and the production can be optimized by changing the media (Example 5). Furthermore, for a given microorganism, the use of different surfactants or solvents may result in increased amount of metabolites or an improved production profile.
For example, PEG 400 and glycerol led to the production of greater amounts of metabolites when Saccharopolyspora erytlzeraea was used (Example 4), while TWEEN 40 significantly increased the number of different metabolites produced by Beauvaria bassiana (Example 6).
[0043] Accordingly, one aspect of the present invention provides a method for producing at least one metabolite of a xenobiotic compound in a microorganism, comprising the steps of:
(a) providing a mixture of the xenobiotic compound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and ' (c) incubating the culture for a period of time sufficient to allow the metabolite to form. The method may optionally further coinprise the step of isolating the metabolite from the culture.
[0044] Certain embodiments of the present invention provide an in vitro biotransformation system for producing significant quantities of metabolites of poorly soluble compounds such as those listed herein, especially immunosuppressive compounds such as cyclosporins (for example, ISA247 and CsA), macrolide lactones (for example, FK506), and triene macrolides (for example, rapamycin). Suitable xenobiotic compounds are discussed in greater detail below.
[0045] After addition of the parent compound-surfactant mixture to the bioreaction mixture that contains the microorganism in growth medium, the bioreaction is allowed to proceed for a time and under conditions which pennit the parent compound to be metabolized.
After the desired time, the metabolites are extracted from the bioreaction mixture, purified by separation, for exainple by chromatography such as high pressure liquid chromatography and mass spectral analysis (HPLC-MS). Nuclear magnetic resonance analysis may be used to verify that the individual metabolites have been isolated from one another and to verify the structure thereof.
Individual metabolites that have been verified as separate chemical entities may be used as standards in subsequent assays.
[0046] A purified metabolite may be used in a TDM assay. For exainple, ISA247 may be administered to an organ transplant patient in a dose sufficient to achieve immunosuppression and prevent the rejection-of a transplanted organ. In order to ensure that the patient is maintaining the proper drug level, and therefore maintaining the proper level of immunosuppression to prevent the rejection of a transplanted organ, a blood sample may be obtained fiom the patient at intervals. Blood levels of ISA247 may be measured. In addition, blood levels of at least one metabolite may be monitored to ensure that the patient's body is metabolizing the drug in a predictable manner. If the patient's own metabolism is not working to eliminate the drug from the patient's system, blood levels of the unmetabolized, active drug may build up, requiring a change in the patient's dosing regimen. Quantification may be achieved by, for example, immunoassay or by HPLC-MS. Similarly, antibodies specific for ISA247 or one of its metabolites may be developed.
[0047] In some embodiments of the present invention, ISA247 in ethanol is mixed with glycerol and then added to a biotransformation system containing Saccharopolyspora erytheraea (e.g., ATCC 11635). In other embodiments PEG 400 is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransfonnation system. In other embodiments castor oil is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system.
In other embodiments isopropyl myristate is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system. In other embodiinents CremophorOO
is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransfonnation system. In other embodiments Labrasol is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system. In other embodiments TWEEN 40 is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system.
Additional exemplary xenobiotic compounds [0048] Additional examples of drugs which are poorly soluble in aqueous solutions include:
analgesics/antipyretics (e.g., aspirin, acetaminophen, ibuprofen, naproxen sodium, buprenorphine, propoxyphene hydrochloride, propoxyphene napsylate, meperidine hydrochloride, hydromorphone hydrochloride, morphine, oxycodone, codeine, dihydrocodeine bitartrate, pentazocine, hydrocodone bitartrate, levorphanol, diflunisal, trolamine salicylate, nalbuphine hydrochloride, mefenamic acid, butorphanol, choline salicylate, butalbital, phenyltoloxamine citrate, diphenhydramine citrate, methotrimeprazine, cinnamedrine hydrochloride, and meprobamate); antiasthamatics (e.g., ketotifen and traxanox); antibiotics (e.g., neomycin, streptomycin, chloramphenicol, cephalosporin, ampicillin, peiiicillin, tetracycline, and ciprofloxacin); antidepressants (e.g., nefopain, oxypertine, doxepin, amoxapine, trazodone, amitriptyline, maprotiline, phenelzine, desipramine, nortriptyline, tranylcypromine, fluoxetine, doxepin, imipramine, imiprainine pamoate, isocarboxazid, trimipramine, and protriptyline); antidiabetics (e.g., biguanides and sulfonylurea derivatives);
antifungal agents (e.g., griseofulvin, ketoconazole, itraconizole, amphotericin B, nystatin, and candicidin);
antihypertensive agents (e.g., propanolol, propafenone, oxyprenolol, nifedipine, reserpine, trimethaphan, phenoxybenzamine, pargyline hydrochloride, deserpidine, diazoxide, guanethidine monosulfate, minoxidil, rescinnamine, sodium nitroprusside, rauwolfia serpentina, alseroxylon, and phentolamine); anti-inflammatories (e.g., (non-steroidal) indomethacin, ketoprofen, flurbiprofen, naproxen, ibuprofen, ramifenazone, piroxicam, (steroidal) cortisone, dexamethasone, fluazacort, celecoxib, rofecoxib, hydrocortisone, prednisolone, and prednisone);
antiteoplastics (e.g., cyclophosphamide, actinomycin, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), methyl-CCNU, cisplatin, etoposide, camptothecin and derivatives thereof, phenesterine, paclitaxel and derivatives thereof, docetaxel and derivatives thereof, vinblastine, vincristine, tamoxifen, and piposulfan); antianxiety agents (e.g., lorazepam, prazepam, chlordiazepoxide, oxazepain, clorazepate dipotassium, diazepam, hydroxyzine pamoate, hydroxyzine hydrochloride, alprazolam, droperidol, halazepam, chlormezanone, and dantrolene);
antimigraine agents (e.g., ergotamine, propanolol, isometheptene mucate, and dichloralphenazone);
sedatives/hypnotics (e.g., barbiturates such as pentobarbital, pentobarbital, and secobarbital;
and benzodiazapines such as flurazepam hydrochloride, triazolam, and midazolam); antianginal agents (e.g., beta-adrenergic blockers; calcium channel blockers such as nifedipine, and diltiazem; and nitrates such as nitroglycerin, isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate);
antipsychotic agents (e.g., haloperidol, loxapine succinate, loxapine hydrochloride, thioridazine, thioridazine hydrochloride, thiothixene, fluphenazine, fluphenazine decanoate, fluphenazine enanthate, trifluoperazirie, chlorpromazine, perphenazine, lithium citrate, and prochlorperazine);
antiarrhytlunics (e.g., bretylium tosylate, esmolol, verapainil, amiodarone, encainide, digoxin, digitoxin, mexiletine, disopyramide phosphate, procainamide, quinidine sulfate, quinidine gluconate, quinidine polygalacturonate, flecainide acetate, tocainide, and lidocaine); antiarthritic agents (e.g., phenylbutazone, sulindac, penicillamine, salsalate, piroxicam, azathioprine, indomethacin, meclofenainate, gold sodium thiomalate, ketoprofen, auranofin, aurothioglucose, and tolmetin sodium); antigout apents (e.g., colchicine, and allopurinol);
anticoagulants (e.g., heparin, heparin sodium, and warfarin sodium); thrombolytic agents (e.g., urokinase, streptokinase, and alteplase); antifibriolytic agents (e.g., aininocaproic acid); hemorheologic agents (e.g., pentoxifylline); antiplatelet agents (e.g., aspirin);
anticonvulsants (e.g., valproic acid, divalproex sodium, phenytoin, phenytoin sodium, clonazepain, primidone, phenobarbitol, carbamazepine, amobarbital sodium, methsuximide, metharbital, mephobarbital, mephenytoin, phensuximide, paramethadione, ethotoin, phenacemide, secobarbitol sodium, clorazepate dipotassium, and trimethadione); antiparkinson agents (e.g., ethosuximide);
antihistamines/antipruritics (e.g., hydroxyzine, diphenhydramine, chlorpheniramine, brompheniramine maleate, cyproheptadine hydrochloride, terfenadine, clemastine fumarate, triprolidine, carbinoxamine, diphenylpyraline, phenindamine, azatadine, tripelennamine, dexchlorpheniramine maleate, methdilazine, and); antibacterial agents (e.g., amikacin sulfate, aztreonam, chloramphenicol, chloramphenicol palmitate, ciprofloxacin, clindamycin, clindamycin palmitate, clindamycin phosphate, metronidazole, metronidazole hydrochloride, gentamicin sulfate, lincomycin hydrochloride, tobramycin sulfate, vancomycin hydrochloride, polymyxin B sulfate, colistimethate sodium, and colistin sulfate); antiviral agents (e.g., interferon alpha, beta or gamma, zidovudine, amantadine hydrochloride, ribavirin, and acyclovir);
antimicrobials (e.g., cephalosporins such as cefazolin sodium, cephradine, cefaclor, cephapirin sodium, ceftizoxime sodium, cefoperazone sodium, cefotetan disodium, cefuroxime e azotil, cefotaxime sodium, cefadroxil monohydrate, cephalexin, cephalothin sodium, cephalexin hydrochloride monohydrate, cefamandole nafate, cefoxitin sodium, cefonicid sodium, ceforanide, cefadroxil, cephradine, and cefuroxime sodium; penicillins such as ampicillin, amoxicillin, penicillin G benzatliine, cyclacillin, ampicillin sodium, penicillin G potassium, penicillin V potassium, piperacillin sodium, oxacillin sodium, bacampicillin hydrochloride, cloxacillin sodium, ticarcillin disodium, azlocillin sodium, carbenicillin indanyl sodium, penicillin G procaine, methicillin sodium, and nafcillin sodium; erythromycins such as erythromycin ethylsuccinate, erythromycin, erythromycin estolate, erythromycin lactobionate, erythromycin stearate, and erythroinycin etliylsuccinate; and tetracyclines such as tetracycline hydrochloride, doxycycline hyclate, and minocycline hydrochloride, azithromycin, clarithromycin); anti-infectives (e.g., GM-CSF); bronchodilators (e.g., sympathomimetics such as epinephrine hydrochloride, metaproterenol sulfate, terbutaline sulfate, isoetharine, isoetharine mesylate, isoetharine hydrochloride, bitolterolmesylate, isoproterenol hydrochloride, terbutaline sulfate, epinephrine bitartrate, metaproterenol sulfate, epinephrine, and epinephrine bitartrate;
anticholinergic agents such as ipratropium bromide; xanthines such as aminophylline, dyphylline, metaproterenol sulfate, and aminophylline; mast cell stabilizers such as cromolyn sodium; steroidal compounds and hormones (e.g., androgens such as danazol, testosterone cypionate, fluoxymesterone, ethyltestosterone, testosterone enathate, methyltestosterone, fluoxymesterone, and testosterone cypionate; estrogens such as estradiol, estropipate, and conjugated estrogens; progestins such as methoxyprogesterone acetate, and norethindrone acetate; corticosteroids such as triamcinolone, betainethasone, betamethasone sodiuin phosphate, dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate prednisone, methylprednisolone acetate suspension, triamcinolone acetonide, methylprednisolone, prednisolone sodium phosphate, methylprednisolone sodium succinate, hydrocortisone sodium succinate, triamcinolone hexacetonide, hydrocortisone, hydrocortisone cypionate, prednisolone, fludrocortisone acetate, paramethasone acetate, prednisolone tebutate, prednisolone acetate, prednisolone sodium phosphate, and hydrocortisone sodium succinate; and thyroid hormones such as levothyroxine sodium); hypoglycemic agents (e.g., glyburide, chlorpropamide, tolbutamide, and tolazamide); hypolipidemic agents (e.g., clofibrate, dextrothyroxine sodium, probucol, pravastitin, atorvastatin, lovastatin, and niacin);
antiulcer/antireflux agents (e.g., famotidine, cimetidine, and ranitidine hydrochloride);
antinauseants/antiemetics (e.g., meclizine hydrochloride, nabilone, prochlorperazine, dimenhydrinate, promethazine hydrochloride, thiethylperazine, and scopolamine); and oil-soluble vitamins. Metabolites of these poorly soluble compounds may be produced using the methods of the instant invention.
Microorganisms [0049] Suitable microorganisms for a successful biotransformation may be chosen based on the presence of microbial enzymes, such as cytochrome P450 enzymes, having the capacity to metabolize the parent compound. Microorganisms that may be useful for biotransformation methods include bacteria, fungi and actinomycetes which possess cytochrome P450 activity.
The organisms having these enzymes can be identified empirically by comparing the metabolites found in the blood or urine after ISA247 administration with those found using a biotransformation or microbial conversion preparation. For exainple, CYP3A4 is a human P450 enzyme that can be characterized by its ability to hydroxylate testosterone, thereby producing 6(3-hydroxytestosterone. The enzyme is inhibited by such compounds as clotrimazole, and naringenin. It is induced by carbamazipine, phenobarbital, and rifampin. An organism, growing in growth media, which expresses an enzyme which has cytochrome P450 activity, should produce 6(3-hydroxytestosterone when testosterone is introduced into the media, and this production should be affected by the known inhibitors and inducers. Other substrates metabolized by CYP3A4 include, for example, acetaminophen, diazepam, theophylline, warfarin, taxol, and nifedipine. Similarly, when these compounds are introduced into media containing a microorganism, if the microorganism expresses the enzyme, it should metabolize the substrate.
[0050] Known and characterized enzymes have known and characterized activity.
By 1'o comparing the structure of the compound to be metabolized with the known activities of enzymes, enzyines can be identified that will be active in metabolizing the compound.
Microorganisms can be screened for the presence of the identified enzyine.
Thus, an aspect of the present invention provides a method of identifying a microorganism suitable for use in a biotransformation systein where the method has the steps: a) comparing the structure of a compound to be metabolized with a known enzyme activities; b) identifying an enzyme that expresses the desired enzyme activity; c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyine in a biotXansformation process to make metabolites of the compound. By using this method, microorganisms which may be useful to produce metabolites of a compound can be identified.
[0051] Alternatively, genetic sequence data may be used to identify potentially useful organisms by comparing the genomic sequence of an organism to the sequence of a known mammalian gene which encodes a cytochrome enzyme, for example CYP3A4.
Microorganisms which have the appropriate genetic sequences, grown in the proper conditions, should express the target enzyme. In addition to reference compounds, compounds that inhibit or induce a particular human P450 enzyme can be tested in both systems.
[0052] Drugs which are known to be metabolized by specific cytochrome enzymes include: (1) acetaminophen, aromatic amines, caffeine, estradiol, imipramine, phenacetin, theophylline and warfarin, broken down by CYP 1A2; (2) amitryptiline, bufurolol, captropril, clozepine, debrisopuine, flecainide, fluoxetine, haloperidol, metoprolol, mexiletine, sparteine, timolol, tomoxetine, propranolol and codeine, broken down by CYP2D6; (3) acetaminophen, diazepam, amiodarone, benzphetamine, carbemazepine, cyclosporine, digitoxin, diltiazem, erythromycin, etopiside, flutamide, imipramine, lidocaine, loratidine, nifedipine, midazolam, retinoic acid, steroids, tamoxifen, taxol, terfenadine, THC, verapamil and warfarin, broken down by CYP3A4.
[0053] Microorganisms that express the CYP3A4 enzyme, and that may be useful for biotransformation methods include but are not limited to: Actinoplanes sp.
(e.g., ATCC No.
53771), Streptofnyces griseus (e.g.e.g., ATCC 13273), Saccharopolyspora erythraea (e.g., ATCC No. 11635), and Streptoinyces setonii (e.g., ATCC No. 39116). Other useful microorganisms that may express cytochrome P450 enzymes include Ainycolata autotrophica (e.g., ATCC No. 35204), Streptomyces californica (e.g., ATCC No. 15436), Saccharopolysora hirsute (e.g., ATCC No. 20501), Streptomyces lavandulae (e.g., ATCC No.
55209), Stretornyces aureofaciens (e.g., ATCC No. 10762), Streptorrayces rimosus (e.g., ATCC No.
28893), Bacillus subtillis (e.g., ATCC No. 55060), and Nocardia asteroids (e.g., ATCC No.
3318), Sacclzaromyces cerevisiae (e.g., ATCC No. 20137 or ATCC No. 64667) Aspergillus nidulans (e.g., ATCC No. 32353) Czcnninghanaella echinulata var. elegans (e.g., ATCC
No.36112), Rhizopus stolonifer, (e.g., ATCC No. 6227b), Candida apicola (e.g., ATCC No.
96134), Coprinus cireneus, (e.g., ATCC No. MYA-727, MYA-726, MYA-728, MYA-729, MYA-730, MYA-731).
[0054] Selection of appropriate culture time, culture conditions, extraction and purification methods is known to those of skill in the art. Growth of the chosen organism may be achieved by a skilled artisan, for example, by the use of an appropriate growth medium containing nutrients such as carbon and nitrogen, a buffering system, and trace elements and of conditions of pH, temperature, and aeration conducive to growtll. Exemplary carbon sources include glucose, maltose, dextrin, starch, lactose, sucrose, molasses, soybean oil, and the like. Suitable nitrogen sources include soybean meal, cotton seed meal, fish meal,, yeast, yeast extract, peptone, rice bran, meat extract, ammonium nitrate, ammoniuin sulfate and the like.
Inorganic salts may be added such as phosphates, sodium chloride, calcium carbonate and the like.
Different growth media may be used depending upon the stage of growth of the organism. 20 [0055] Exemplary conditions and media for growth of microorganisms suitable for use in the bioconversion of cyclosporins and cyclosporine derivatives thereof by Saccharopolyspora eiythraea (for example, ATCC 11635), Saccharopolysora hirsute (for example, ATCC 20501), Amycolata autotrophica (for example, ATCC 35204), are provided in Corconan, Methods in Enzymology 43: 487-498 (1975), US Pat. Nos. 5,124,258; 6,043,064; and 6,331,622. Conditions for growth of Actinoplanes sp. (for exainple, ATCC No. 53771) are exemplified in US Pat: No.
5,270,187.
[00561 Exemplary growth conditions for microbial bioconversion of macrolides to their hydroxylated and/or demethylated metabolites include: 1) growth conditions as disclosed for the demethylation of L-679,934 (FK-506) to its metabolite, L-683,519, using Actinomycete sp.
(Merck Culture Collection MA 6474; ATCC No. 53828) exemplified in US Pat. No.
5,268,370;
and 2) demethylation of L-679,934 to L-682,993 or L-683,590 to L-683,742) by Actinoplanes sp.
(ATCC No. 53771) using conditions for growth provided in US Pat. No. 5,202, 258.
Actinoplanes spp. ATCC 53771, Saccharopolyspora erthyreae ATCC 11653, Streptomyces lavandulae ATCC 55209, Stretomyces aureofaciens ATCC 10762, Streptoin.yces rimoszts ATCC
28893, Bacillus subtillis ATCC 55060 and Nocardia asteroids ATCC 3318 may be used to produce hydroxylated (for example, 24-OH rapamycin) and/or demethylated metabolites (for example, 39-O-demethylrapamycin) of rapamycin (Kuhnt, M., et al., 1997, Enzyme and Microbial Technology 21: 405-412).
Surfactants [0057] Suitable surfactants for use in an embodiment of the inventive method may be able to withstand autoclaving prior to being introduced into a microbial growth environment. Suitable surfactants are biocompatible surfactants and include but are not limited to nonionic surfactants such as polyethylene glycols for example PEG 300, PEG 400, PEG 600 (also known as Lutrol E 300, LutrolO E 400, Lutrol E 600 Lutrol F 127, and Lutrol(b F 68 from BASF);
caprylocaproyl macrogol-8 glycerides such as Labrasol (Gatte Fosse, Cedex France);
polyoxyethylene sorbitan fatty acid esters such as Tween 20, Tween 21, Tween 40, Tween 80, TweenO 80K, Tween 81 and Tween 85 (ICI Americas Inc., Bridgewater NJ, obtained from Aldrich Chemical Company Inc., Milwaukee Wis.); glycerine (BDH
Fine Chemicals, Toronto Ont.); castor oil (Wiler Fine Chemicals Ltd, London Ont.);
Isopropyl myristate (Wiler Fine Chemicals Ltd, London Ont.); Cremophor EL (Sigma Chemical, St Louis MO); and poloxamers such as Pluronics F127 and Pluronics L108 (BASF).
Other surfactants that may be used include those that can act as lubricants or emulsifiers such as tyloxapol [4-(1,1,3,3-tetramethylbutyl)phenol polymer with formaldehyde and oxirane];
polyethoxylated castor oils such as Cremophor(M A25, Cremophor A6, Cremophor EL, Cremophor ELP, Cremophor RH from BASF and Alkamuls EL620 from Rhone Poulenc Co;
polyethoxylated hydrogenated castor oils, such as HCO-40; and polyethylene 9 castor oil.
[0058] Other surfactants that may be used include; polysorbate 20, polysorbate 60, and polysorbate 80; Cremophor RH; poloxamers; Pluonics L10, L31, L35, L42, L43, L44, L61, L62, L63, L72, L81, L101, L121, L122; PEG 20 almond glyceride; PEG 20 corn glyceride; and the like. Suitable surfactants also include alkylglucosides; alkylmaltosides;
alkylthioglucosides;
lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols;
polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene sterols; polyoxyethylene vegetable oils;
polyoxyethylene hydrogenated vegetable oils; polyoxyethylene alkylethers;
polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters;
polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols such as PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl:trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-101aurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl- 10 oleate, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer; PEG-3 5 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, and PEG-24 cholesterol, a poloxamer. In addition, oils such as almond oil;
babassu oil; borage oil; blackcurrant seed oil; canola oil; coconut oil; corn oil; cottonseed oil;
evening primrose oil;
grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil;
rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil;
sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil;
hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; soy oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate;
glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate; glyceryl tricaprylate/caprate/stearate;
saturated polyglycolized glycerides; linoleic glycerides; caprylic/capric glycerides may be used. In addition, a mixture of surfactants and/or oils and/or alcohols may be used.
[0059] In some einbodiments of the present invention, the selected lipophilic xenobiotic is mixed with an alkanol and a suitable nonionic surfactant before addition to an actively growing microbial culture. If the parent coinpound is mixed with an alcohol, the alcohol may be ethanol.
Additional suitable alcohols include: methanol, isopropanol, 1-propanol, and other suitable alcohols well known in the art.
Solvents [0060] In some embodiments of the present invention, the xenobiotic coinpound is mixed with a solvent before being added to a microorganism culture. The solvents may be sterilized prior to mixing with the xenobiotic compound. Optionally, a surfactant is also added to the xenobiotic compound - solvent mixture. Suitable solvents of the present invention may be any solvent that does not inhibit the growth and metabolism of the microorganism. The solvent may be non-polar, polar aprotic, or polar protic. For example, the solvents include the hydrocarbon series solvents, such as benzene, toluene, n-hexane, cyclohexane, etc.; ether series solvents such as diethyl ether, tetrahydrofuran, 1,4-dioxane, methyl t-butyl ether, dimethoxyethane, ethylene glycol dimethyl ether, etc.; alcohols such as methanol, ethanol, 1-propanol, isopropanol, etc.;
halogen-containing solvents such as methylene chloride, chloroform, 1, 1, 1 -trichloroethane, etc.;
and other solvents such as dimethylformamide, N-methylpyrrolidone, hexamethylphosphorotriamide, etc. The solvent is preferably not DMSO.
[0061] The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of the present invention. While this invention is particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be inade therein without departing from the spirit and scope of the invention as defined by the appended claims.
EXAMPLES
[0062] In the examples below, the following abbreviations have the following meanings.
Abbreviations not defined have their generally accepted meanings.
C = degree Celsius hr = hour min = minute sec or s= second M = micromolar mM = millimolar M = molar ml = milliliter l = microliter mg = milligram g = microgratn mol = mole pmol = picomole ATCC = American Type Culture Collection PBS = phosphate buffered saline CSA = cyclosporin A
TDM = therapeutic dose monitoring LC = liquid chromatography MS = mass spectrometry PEG = polyethylene glycol General Material and Methods Liquid Chrofnatographic (LC) Conditions [0063] For Liquid Chromatography (LC or HPLC) a column having a stationary phase formed by chemically bonding a long-chain hydrocarbon group to a porous silica matrix, a Waters Symmetry C8, 2.1X50mm, 3.5 m analytical column (Waters cat# WAT 200624) with a guard column 2 x 20mm (Upchurch Scientific cat# C-130B) packed with Perisorb RP-8 (Upchurch Scientific cat# C-601) was used. The solvent percentages and flow rates utilized in the LC
program are given in Table 2:
0.2 % GAA +
> and Where R2 is selected from the group consisting of CH3 and H; where R3)is selected from the group consisting of CH2CH(CH3)2 and CH2C(CH3)20H; and where R4 is selected from the group consisting of CH(CH3)2 and C(CH3)20H.
[0034] Structures of ISA247 metabolites which are modifications at amino acid-1 of the ISA247 compound are illustrated in Table 1. The boxes represent amino acids 2-11 which form the ring portion of the cyclosporin structure with the modified amino acid-l, see Figure 1. Table 1 is not an exhaustive list of ISA247 metabolites that are modified at amino acid-1. For example, amino acid 1 metabolites may include 5, 6, 7 or 8 member rings.
Table 1: Amino Acid 1 Metabolites of ISA
IM1-e-1 CH CH
I91 -e-1 IMl-e-1 IM1-e-2 HO
CH
IM 1-e-2 IM1-e-3 O
HO
CH
IM 1-e-3 IM1-d-1 OH H
H/' HO
+
HO HO
IM1Hd-1 IM1 d1 TM 1 -d-2 HO HO
, HopO~' Ho H HO
cH~ CH~
IMI-J-? IMI-J-?
IM 1-d-3 OH OH
OH OH HO HO
CH3 CH, IMl d-3 IM1Hd-3 IMl-d-4 I OH I OH I OH onIIOH
HO HO
H CH Ho OH' HO CH~ Ho CH~
IMIHJ-4 IMI-J=A IMICJ-4 IMI-J-4 -_, IMl-c-1 H H
O
CH~ 9--F-ICHIMI-ul IM1-c-2 OH
O
CHa HO
HO OH
COzH
HO
[0035] ISA247 metabolites include N-demethylated metabolites where the N-demethylation occurs at at least one methylated nitrogen of the amide linkage of an alnino acid, for example, IM4n, (or ISA247 Metabolite, N-demethylation at amino acid-4). N-demethylation can occur at amino acid-3 (IM3n), amino acid=4 (IM4n), amino acid-6 (IM6n), amino acid-9 (IM9n), amino acid- 10 (IM10n) or ainino acid-11 (IM 11 n). ISA247 metabolites also include hydroxylated metabolites where the hydroxylation occurs at at least one methyl leucine amino acid, for example amino acids 4, 6, 9 or 10 (IM4, IM6, IM9 or IM10), or at valine residue 5(IM5) or at methyl valine residue 11 (IMl 1). IM46 are hydroxylated at both ainino acids 4 and 6, IM49 are hydroxylated at both amino acids 4 and 9, and so on. Combinations of N-demethylated and hydroxylated metabolites can occur, as well as combinations of the metabolites which are alterations at amino acid-1, as shown in Table 1, with N-demethylations or hydroxylations.
ISA247 nzetabolites also include metabolites which are glucuronide, sulfonide, glycosylated and phosphorylated derivatives of hydroxylated metabolites of ISA247. U.S. Pat.
Application No.
_(Attorney Docket Number 16593-009001, filed December 19, 2005) co-pending and commonly assigned to the assignee provides ISA247 metabolites and uses thereof.
Methods of preparing ISA247 metabolites [0036] Metabolites of ISA247 were first analyzed using human whole blood of a subject who had received a 50:50 mixture of cis:trans ISA247 (Example 1). Figure 3 is an HPLC scan illustrating the metabolite profile of metabolites isolated from the whole blood of this subject.
Using organic extractions on human whole blood, metabolites were extracted, dried, reconstituted in methanol and identified using chromatographic techniques coupled with mass spectrometry. As shown in Figure 3, at least three diol , two hydroxylated and three N-demethylated metabolites were detectable in human whole blood.
[0037] A dog liver microsome preparation was also used to produce 1SA247 metabolites (Example 2). While ISA247 metabolites can be produced in this manner, the yield was low and the cost was high. Therefore, it is not practical to obtain meaningful quantities of ISA247 metabolites using this approach.
[0038] To our knowledge, prior to the present invention, conventional biotransformation methods had not been reported as producing quantities of metabolites of CsA
and ISA247, perhaps because of the lipophilic nature of these compounds. Without wislung to be bound by any theory, we believe the problem is that a hydrophobic compound, such as ISA247, has a tendency to adhere to the surfaces of filters, columns, and other hardware used to carry out the culture and process the product metabolites. Also, these highly lipophilic coinpounds do not go into solution in the aqueous environment of microorganisms in culture.
Cultured microorganisms may not be able to access these lipophilic compounds to metabolize them. In some aspects, providing drug to a microbial growth preparation is not unlike providing drug to a mammal. A formulation that increases the bioavailability of the drug may be necessary.
[0039] In humans, cytochrome P450 enzymes are known to fonn metabolites from CsA. It has been found that cytochrome P450 enzymes also act to form ISA247 metabolites.
Specifically, the cytochrome P450 enzyine CYP3A4 has been identified as the enzyme responsible for cyclosporin and ISA247 metabolism. In order to produce a metabolite profile that is similar to that obtained from humans, the biotransformation system must utilize a microorganism which has the microbial equivalent of the human cytochrome P450 enzyme, grown in a medium and under culture conditions suitable for active growth and metabolism of the microorganism.
[0040] Biotransformation methods are exemplified in Smith et al. (Arch.
Biochem. Biophys.
(1974) 161: 551-558). Urlacker and Schmid (Curr Opin Biotechnol. (2002) 13(6):557-64) suggest that biotransformations could be performed using prokaryotic P450 monooxygenase enzymes. Venisetty andCiddi (Current Pharmaceutical Biotechnology (2003) 4(3):153-167) have proposed application of microorganisms to natural drugs to find novel drugs.
[0041] Biotransformation of cyclosporin A solubilized in methanol by Sebekia beraihana to [y-hydroxy-MeLeu]4 cyclosporin (AM4) and to [,y-hydroxy-MeLeu]4 [y-hydroxy-MeLeu]6 cyclosporin (AM46) has been disclosed in US Pat. No. 6,255,100. However, it should be noted that when CsA is administered to a human, the predominate metabolites that are produced and monitored for TDM are AM 1 (a metabolite of CsA that is hydroxylated at amino acid-l, MeBmt), AM9 (a metabolite that is hydroxylated at the MeLeu at amino acid position 9) and AM4n (a metabolite of CsA that is demethylated at the Meleu at amino acid position 4) (LeGatt et al., Clin Biochem. (1994) 27(1):43-8). Thus, Sebekia benihana exemplifies a microorganism that does not provide a metabolic profile that mimics the mainmalian metabolic profile of CsA.
[0042] We demonstrate herein that biotransformation can be used to produce metabolites of ISA247. As shown in Example 3, by delivering a mixture containing ISA247 and the surfactant TWEENO 40 (polyoxyethylene sorbitan monopalmitate) to Saccharopolyspora erytlzey-aea, all the main categories of ISA247 metabolites found in human blood were produced.
Specifically, seven ISA247 metabolites were detected: IM4n (ISA247 Metabolite that is N-demethylated at amino acid-4), IM9 (ISA247 Metabolite that is hydroxylated at amino acid-9), IM4 (ISA247 Metabolite that is hydroxylated at amino acid-4), IM1-c-1(See table 1), IM1-d-1 (Table 1), IMl-d-2 (Table 1) and IMl-d-3 (Table 1). Different microorganisms produce different types, numbers and quantities of ISA247 metabolites, and the production can be optimized by changing the media (Example 5). Furthermore, for a given microorganism, the use of different surfactants or solvents may result in increased amount of metabolites or an improved production profile.
For example, PEG 400 and glycerol led to the production of greater amounts of metabolites when Saccharopolyspora erytlzeraea was used (Example 4), while TWEEN 40 significantly increased the number of different metabolites produced by Beauvaria bassiana (Example 6).
[0043] Accordingly, one aspect of the present invention provides a method for producing at least one metabolite of a xenobiotic compound in a microorganism, comprising the steps of:
(a) providing a mixture of the xenobiotic compound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and ' (c) incubating the culture for a period of time sufficient to allow the metabolite to form. The method may optionally further coinprise the step of isolating the metabolite from the culture.
[0044] Certain embodiments of the present invention provide an in vitro biotransformation system for producing significant quantities of metabolites of poorly soluble compounds such as those listed herein, especially immunosuppressive compounds such as cyclosporins (for example, ISA247 and CsA), macrolide lactones (for example, FK506), and triene macrolides (for example, rapamycin). Suitable xenobiotic compounds are discussed in greater detail below.
[0045] After addition of the parent compound-surfactant mixture to the bioreaction mixture that contains the microorganism in growth medium, the bioreaction is allowed to proceed for a time and under conditions which pennit the parent compound to be metabolized.
After the desired time, the metabolites are extracted from the bioreaction mixture, purified by separation, for exainple by chromatography such as high pressure liquid chromatography and mass spectral analysis (HPLC-MS). Nuclear magnetic resonance analysis may be used to verify that the individual metabolites have been isolated from one another and to verify the structure thereof.
Individual metabolites that have been verified as separate chemical entities may be used as standards in subsequent assays.
[0046] A purified metabolite may be used in a TDM assay. For exainple, ISA247 may be administered to an organ transplant patient in a dose sufficient to achieve immunosuppression and prevent the rejection-of a transplanted organ. In order to ensure that the patient is maintaining the proper drug level, and therefore maintaining the proper level of immunosuppression to prevent the rejection of a transplanted organ, a blood sample may be obtained fiom the patient at intervals. Blood levels of ISA247 may be measured. In addition, blood levels of at least one metabolite may be monitored to ensure that the patient's body is metabolizing the drug in a predictable manner. If the patient's own metabolism is not working to eliminate the drug from the patient's system, blood levels of the unmetabolized, active drug may build up, requiring a change in the patient's dosing regimen. Quantification may be achieved by, for example, immunoassay or by HPLC-MS. Similarly, antibodies specific for ISA247 or one of its metabolites may be developed.
[0047] In some embodiments of the present invention, ISA247 in ethanol is mixed with glycerol and then added to a biotransformation system containing Saccharopolyspora erytheraea (e.g., ATCC 11635). In other embodiments PEG 400 is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransfonnation system. In other embodiments castor oil is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system.
In other embodiments isopropyl myristate is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system. In other embodiinents CremophorOO
is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransfonnation system. In other embodiments Labrasol is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system. In other embodiments TWEEN 40 is mixed with ISA247 in ethanol prior to the addition of ISA247 to the biotransformation system.
Additional exemplary xenobiotic compounds [0048] Additional examples of drugs which are poorly soluble in aqueous solutions include:
analgesics/antipyretics (e.g., aspirin, acetaminophen, ibuprofen, naproxen sodium, buprenorphine, propoxyphene hydrochloride, propoxyphene napsylate, meperidine hydrochloride, hydromorphone hydrochloride, morphine, oxycodone, codeine, dihydrocodeine bitartrate, pentazocine, hydrocodone bitartrate, levorphanol, diflunisal, trolamine salicylate, nalbuphine hydrochloride, mefenamic acid, butorphanol, choline salicylate, butalbital, phenyltoloxamine citrate, diphenhydramine citrate, methotrimeprazine, cinnamedrine hydrochloride, and meprobamate); antiasthamatics (e.g., ketotifen and traxanox); antibiotics (e.g., neomycin, streptomycin, chloramphenicol, cephalosporin, ampicillin, peiiicillin, tetracycline, and ciprofloxacin); antidepressants (e.g., nefopain, oxypertine, doxepin, amoxapine, trazodone, amitriptyline, maprotiline, phenelzine, desipramine, nortriptyline, tranylcypromine, fluoxetine, doxepin, imipramine, imiprainine pamoate, isocarboxazid, trimipramine, and protriptyline); antidiabetics (e.g., biguanides and sulfonylurea derivatives);
antifungal agents (e.g., griseofulvin, ketoconazole, itraconizole, amphotericin B, nystatin, and candicidin);
antihypertensive agents (e.g., propanolol, propafenone, oxyprenolol, nifedipine, reserpine, trimethaphan, phenoxybenzamine, pargyline hydrochloride, deserpidine, diazoxide, guanethidine monosulfate, minoxidil, rescinnamine, sodium nitroprusside, rauwolfia serpentina, alseroxylon, and phentolamine); anti-inflammatories (e.g., (non-steroidal) indomethacin, ketoprofen, flurbiprofen, naproxen, ibuprofen, ramifenazone, piroxicam, (steroidal) cortisone, dexamethasone, fluazacort, celecoxib, rofecoxib, hydrocortisone, prednisolone, and prednisone);
antiteoplastics (e.g., cyclophosphamide, actinomycin, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, carboplatin, carmustine (BCNU), methyl-CCNU, cisplatin, etoposide, camptothecin and derivatives thereof, phenesterine, paclitaxel and derivatives thereof, docetaxel and derivatives thereof, vinblastine, vincristine, tamoxifen, and piposulfan); antianxiety agents (e.g., lorazepam, prazepam, chlordiazepoxide, oxazepain, clorazepate dipotassium, diazepam, hydroxyzine pamoate, hydroxyzine hydrochloride, alprazolam, droperidol, halazepam, chlormezanone, and dantrolene);
antimigraine agents (e.g., ergotamine, propanolol, isometheptene mucate, and dichloralphenazone);
sedatives/hypnotics (e.g., barbiturates such as pentobarbital, pentobarbital, and secobarbital;
and benzodiazapines such as flurazepam hydrochloride, triazolam, and midazolam); antianginal agents (e.g., beta-adrenergic blockers; calcium channel blockers such as nifedipine, and diltiazem; and nitrates such as nitroglycerin, isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate);
antipsychotic agents (e.g., haloperidol, loxapine succinate, loxapine hydrochloride, thioridazine, thioridazine hydrochloride, thiothixene, fluphenazine, fluphenazine decanoate, fluphenazine enanthate, trifluoperazirie, chlorpromazine, perphenazine, lithium citrate, and prochlorperazine);
antiarrhytlunics (e.g., bretylium tosylate, esmolol, verapainil, amiodarone, encainide, digoxin, digitoxin, mexiletine, disopyramide phosphate, procainamide, quinidine sulfate, quinidine gluconate, quinidine polygalacturonate, flecainide acetate, tocainide, and lidocaine); antiarthritic agents (e.g., phenylbutazone, sulindac, penicillamine, salsalate, piroxicam, azathioprine, indomethacin, meclofenainate, gold sodium thiomalate, ketoprofen, auranofin, aurothioglucose, and tolmetin sodium); antigout apents (e.g., colchicine, and allopurinol);
anticoagulants (e.g., heparin, heparin sodium, and warfarin sodium); thrombolytic agents (e.g., urokinase, streptokinase, and alteplase); antifibriolytic agents (e.g., aininocaproic acid); hemorheologic agents (e.g., pentoxifylline); antiplatelet agents (e.g., aspirin);
anticonvulsants (e.g., valproic acid, divalproex sodium, phenytoin, phenytoin sodium, clonazepain, primidone, phenobarbitol, carbamazepine, amobarbital sodium, methsuximide, metharbital, mephobarbital, mephenytoin, phensuximide, paramethadione, ethotoin, phenacemide, secobarbitol sodium, clorazepate dipotassium, and trimethadione); antiparkinson agents (e.g., ethosuximide);
antihistamines/antipruritics (e.g., hydroxyzine, diphenhydramine, chlorpheniramine, brompheniramine maleate, cyproheptadine hydrochloride, terfenadine, clemastine fumarate, triprolidine, carbinoxamine, diphenylpyraline, phenindamine, azatadine, tripelennamine, dexchlorpheniramine maleate, methdilazine, and); antibacterial agents (e.g., amikacin sulfate, aztreonam, chloramphenicol, chloramphenicol palmitate, ciprofloxacin, clindamycin, clindamycin palmitate, clindamycin phosphate, metronidazole, metronidazole hydrochloride, gentamicin sulfate, lincomycin hydrochloride, tobramycin sulfate, vancomycin hydrochloride, polymyxin B sulfate, colistimethate sodium, and colistin sulfate); antiviral agents (e.g., interferon alpha, beta or gamma, zidovudine, amantadine hydrochloride, ribavirin, and acyclovir);
antimicrobials (e.g., cephalosporins such as cefazolin sodium, cephradine, cefaclor, cephapirin sodium, ceftizoxime sodium, cefoperazone sodium, cefotetan disodium, cefuroxime e azotil, cefotaxime sodium, cefadroxil monohydrate, cephalexin, cephalothin sodium, cephalexin hydrochloride monohydrate, cefamandole nafate, cefoxitin sodium, cefonicid sodium, ceforanide, cefadroxil, cephradine, and cefuroxime sodium; penicillins such as ampicillin, amoxicillin, penicillin G benzatliine, cyclacillin, ampicillin sodium, penicillin G potassium, penicillin V potassium, piperacillin sodium, oxacillin sodium, bacampicillin hydrochloride, cloxacillin sodium, ticarcillin disodium, azlocillin sodium, carbenicillin indanyl sodium, penicillin G procaine, methicillin sodium, and nafcillin sodium; erythromycins such as erythromycin ethylsuccinate, erythromycin, erythromycin estolate, erythromycin lactobionate, erythromycin stearate, and erythroinycin etliylsuccinate; and tetracyclines such as tetracycline hydrochloride, doxycycline hyclate, and minocycline hydrochloride, azithromycin, clarithromycin); anti-infectives (e.g., GM-CSF); bronchodilators (e.g., sympathomimetics such as epinephrine hydrochloride, metaproterenol sulfate, terbutaline sulfate, isoetharine, isoetharine mesylate, isoetharine hydrochloride, bitolterolmesylate, isoproterenol hydrochloride, terbutaline sulfate, epinephrine bitartrate, metaproterenol sulfate, epinephrine, and epinephrine bitartrate;
anticholinergic agents such as ipratropium bromide; xanthines such as aminophylline, dyphylline, metaproterenol sulfate, and aminophylline; mast cell stabilizers such as cromolyn sodium; steroidal compounds and hormones (e.g., androgens such as danazol, testosterone cypionate, fluoxymesterone, ethyltestosterone, testosterone enathate, methyltestosterone, fluoxymesterone, and testosterone cypionate; estrogens such as estradiol, estropipate, and conjugated estrogens; progestins such as methoxyprogesterone acetate, and norethindrone acetate; corticosteroids such as triamcinolone, betainethasone, betamethasone sodiuin phosphate, dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate prednisone, methylprednisolone acetate suspension, triamcinolone acetonide, methylprednisolone, prednisolone sodium phosphate, methylprednisolone sodium succinate, hydrocortisone sodium succinate, triamcinolone hexacetonide, hydrocortisone, hydrocortisone cypionate, prednisolone, fludrocortisone acetate, paramethasone acetate, prednisolone tebutate, prednisolone acetate, prednisolone sodium phosphate, and hydrocortisone sodium succinate; and thyroid hormones such as levothyroxine sodium); hypoglycemic agents (e.g., glyburide, chlorpropamide, tolbutamide, and tolazamide); hypolipidemic agents (e.g., clofibrate, dextrothyroxine sodium, probucol, pravastitin, atorvastatin, lovastatin, and niacin);
antiulcer/antireflux agents (e.g., famotidine, cimetidine, and ranitidine hydrochloride);
antinauseants/antiemetics (e.g., meclizine hydrochloride, nabilone, prochlorperazine, dimenhydrinate, promethazine hydrochloride, thiethylperazine, and scopolamine); and oil-soluble vitamins. Metabolites of these poorly soluble compounds may be produced using the methods of the instant invention.
Microorganisms [0049] Suitable microorganisms for a successful biotransformation may be chosen based on the presence of microbial enzymes, such as cytochrome P450 enzymes, having the capacity to metabolize the parent compound. Microorganisms that may be useful for biotransformation methods include bacteria, fungi and actinomycetes which possess cytochrome P450 activity.
The organisms having these enzymes can be identified empirically by comparing the metabolites found in the blood or urine after ISA247 administration with those found using a biotransformation or microbial conversion preparation. For exainple, CYP3A4 is a human P450 enzyme that can be characterized by its ability to hydroxylate testosterone, thereby producing 6(3-hydroxytestosterone. The enzyme is inhibited by such compounds as clotrimazole, and naringenin. It is induced by carbamazipine, phenobarbital, and rifampin. An organism, growing in growth media, which expresses an enzyme which has cytochrome P450 activity, should produce 6(3-hydroxytestosterone when testosterone is introduced into the media, and this production should be affected by the known inhibitors and inducers. Other substrates metabolized by CYP3A4 include, for example, acetaminophen, diazepam, theophylline, warfarin, taxol, and nifedipine. Similarly, when these compounds are introduced into media containing a microorganism, if the microorganism expresses the enzyme, it should metabolize the substrate.
[0050] Known and characterized enzymes have known and characterized activity.
By 1'o comparing the structure of the compound to be metabolized with the known activities of enzymes, enzyines can be identified that will be active in metabolizing the compound.
Microorganisms can be screened for the presence of the identified enzyine.
Thus, an aspect of the present invention provides a method of identifying a microorganism suitable for use in a biotransformation systein where the method has the steps: a) comparing the structure of a compound to be metabolized with a known enzyme activities; b) identifying an enzyme that expresses the desired enzyme activity; c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyine in a biotXansformation process to make metabolites of the compound. By using this method, microorganisms which may be useful to produce metabolites of a compound can be identified.
[0051] Alternatively, genetic sequence data may be used to identify potentially useful organisms by comparing the genomic sequence of an organism to the sequence of a known mammalian gene which encodes a cytochrome enzyme, for example CYP3A4.
Microorganisms which have the appropriate genetic sequences, grown in the proper conditions, should express the target enzyme. In addition to reference compounds, compounds that inhibit or induce a particular human P450 enzyme can be tested in both systems.
[0052] Drugs which are known to be metabolized by specific cytochrome enzymes include: (1) acetaminophen, aromatic amines, caffeine, estradiol, imipramine, phenacetin, theophylline and warfarin, broken down by CYP 1A2; (2) amitryptiline, bufurolol, captropril, clozepine, debrisopuine, flecainide, fluoxetine, haloperidol, metoprolol, mexiletine, sparteine, timolol, tomoxetine, propranolol and codeine, broken down by CYP2D6; (3) acetaminophen, diazepam, amiodarone, benzphetamine, carbemazepine, cyclosporine, digitoxin, diltiazem, erythromycin, etopiside, flutamide, imipramine, lidocaine, loratidine, nifedipine, midazolam, retinoic acid, steroids, tamoxifen, taxol, terfenadine, THC, verapamil and warfarin, broken down by CYP3A4.
[0053] Microorganisms that express the CYP3A4 enzyme, and that may be useful for biotransformation methods include but are not limited to: Actinoplanes sp.
(e.g., ATCC No.
53771), Streptofnyces griseus (e.g.e.g., ATCC 13273), Saccharopolyspora erythraea (e.g., ATCC No. 11635), and Streptoinyces setonii (e.g., ATCC No. 39116). Other useful microorganisms that may express cytochrome P450 enzymes include Ainycolata autotrophica (e.g., ATCC No. 35204), Streptomyces californica (e.g., ATCC No. 15436), Saccharopolysora hirsute (e.g., ATCC No. 20501), Streptomyces lavandulae (e.g., ATCC No.
55209), Stretornyces aureofaciens (e.g., ATCC No. 10762), Streptorrayces rimosus (e.g., ATCC No.
28893), Bacillus subtillis (e.g., ATCC No. 55060), and Nocardia asteroids (e.g., ATCC No.
3318), Sacclzaromyces cerevisiae (e.g., ATCC No. 20137 or ATCC No. 64667) Aspergillus nidulans (e.g., ATCC No. 32353) Czcnninghanaella echinulata var. elegans (e.g., ATCC
No.36112), Rhizopus stolonifer, (e.g., ATCC No. 6227b), Candida apicola (e.g., ATCC No.
96134), Coprinus cireneus, (e.g., ATCC No. MYA-727, MYA-726, MYA-728, MYA-729, MYA-730, MYA-731).
[0054] Selection of appropriate culture time, culture conditions, extraction and purification methods is known to those of skill in the art. Growth of the chosen organism may be achieved by a skilled artisan, for example, by the use of an appropriate growth medium containing nutrients such as carbon and nitrogen, a buffering system, and trace elements and of conditions of pH, temperature, and aeration conducive to growtll. Exemplary carbon sources include glucose, maltose, dextrin, starch, lactose, sucrose, molasses, soybean oil, and the like. Suitable nitrogen sources include soybean meal, cotton seed meal, fish meal,, yeast, yeast extract, peptone, rice bran, meat extract, ammonium nitrate, ammoniuin sulfate and the like.
Inorganic salts may be added such as phosphates, sodium chloride, calcium carbonate and the like.
Different growth media may be used depending upon the stage of growth of the organism. 20 [0055] Exemplary conditions and media for growth of microorganisms suitable for use in the bioconversion of cyclosporins and cyclosporine derivatives thereof by Saccharopolyspora eiythraea (for example, ATCC 11635), Saccharopolysora hirsute (for example, ATCC 20501), Amycolata autotrophica (for example, ATCC 35204), are provided in Corconan, Methods in Enzymology 43: 487-498 (1975), US Pat. Nos. 5,124,258; 6,043,064; and 6,331,622. Conditions for growth of Actinoplanes sp. (for exainple, ATCC No. 53771) are exemplified in US Pat: No.
5,270,187.
[00561 Exemplary growth conditions for microbial bioconversion of macrolides to their hydroxylated and/or demethylated metabolites include: 1) growth conditions as disclosed for the demethylation of L-679,934 (FK-506) to its metabolite, L-683,519, using Actinomycete sp.
(Merck Culture Collection MA 6474; ATCC No. 53828) exemplified in US Pat. No.
5,268,370;
and 2) demethylation of L-679,934 to L-682,993 or L-683,590 to L-683,742) by Actinoplanes sp.
(ATCC No. 53771) using conditions for growth provided in US Pat. No. 5,202, 258.
Actinoplanes spp. ATCC 53771, Saccharopolyspora erthyreae ATCC 11653, Streptomyces lavandulae ATCC 55209, Stretomyces aureofaciens ATCC 10762, Streptoin.yces rimoszts ATCC
28893, Bacillus subtillis ATCC 55060 and Nocardia asteroids ATCC 3318 may be used to produce hydroxylated (for example, 24-OH rapamycin) and/or demethylated metabolites (for example, 39-O-demethylrapamycin) of rapamycin (Kuhnt, M., et al., 1997, Enzyme and Microbial Technology 21: 405-412).
Surfactants [0057] Suitable surfactants for use in an embodiment of the inventive method may be able to withstand autoclaving prior to being introduced into a microbial growth environment. Suitable surfactants are biocompatible surfactants and include but are not limited to nonionic surfactants such as polyethylene glycols for example PEG 300, PEG 400, PEG 600 (also known as Lutrol E 300, LutrolO E 400, Lutrol E 600 Lutrol F 127, and Lutrol(b F 68 from BASF);
caprylocaproyl macrogol-8 glycerides such as Labrasol (Gatte Fosse, Cedex France);
polyoxyethylene sorbitan fatty acid esters such as Tween 20, Tween 21, Tween 40, Tween 80, TweenO 80K, Tween 81 and Tween 85 (ICI Americas Inc., Bridgewater NJ, obtained from Aldrich Chemical Company Inc., Milwaukee Wis.); glycerine (BDH
Fine Chemicals, Toronto Ont.); castor oil (Wiler Fine Chemicals Ltd, London Ont.);
Isopropyl myristate (Wiler Fine Chemicals Ltd, London Ont.); Cremophor EL (Sigma Chemical, St Louis MO); and poloxamers such as Pluronics F127 and Pluronics L108 (BASF).
Other surfactants that may be used include those that can act as lubricants or emulsifiers such as tyloxapol [4-(1,1,3,3-tetramethylbutyl)phenol polymer with formaldehyde and oxirane];
polyethoxylated castor oils such as Cremophor(M A25, Cremophor A6, Cremophor EL, Cremophor ELP, Cremophor RH from BASF and Alkamuls EL620 from Rhone Poulenc Co;
polyethoxylated hydrogenated castor oils, such as HCO-40; and polyethylene 9 castor oil.
[0058] Other surfactants that may be used include; polysorbate 20, polysorbate 60, and polysorbate 80; Cremophor RH; poloxamers; Pluonics L10, L31, L35, L42, L43, L44, L61, L62, L63, L72, L81, L101, L121, L122; PEG 20 almond glyceride; PEG 20 corn glyceride; and the like. Suitable surfactants also include alkylglucosides; alkylmaltosides;
alkylthioglucosides;
lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols;
polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters;
polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene sterols; polyoxyethylene vegetable oils;
polyoxyethylene hydrogenated vegetable oils; polyoxyethylene alkylethers;
polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters;
polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters;
polyoxyethylene glycerides; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols such as PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl:trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-101aurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl- 10 oleate, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, a poloxamer; PEG-3 5 castor oil, PEG-40 hydrogenated castor oil, PEG-60 corn oil, PEG-25 glyceryl trioleate, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polysorbate 20, polysorbate 80, tocopheryl PEG-1000 succinate, and PEG-24 cholesterol, a poloxamer. In addition, oils such as almond oil;
babassu oil; borage oil; blackcurrant seed oil; canola oil; coconut oil; corn oil; cottonseed oil;
evening primrose oil;
grapeseed oil; groundnut oil; mustard seed oil; olive oil; palm oil; palm kernel oil; peanut oil;
rapeseed oil; safflower oil; sesame oil; shark liver oil; soybean oil;
sunflower oil; hydrogenated castor oil; hydrogenated coconut oil; hydrogenated palm oil; hydrogenated soybean oil;
hydrogenated vegetable oil; hydrogenated cottonseed and castor oil; partially hydrogenated soybean oil; soy oil; glyceryl tricaproate; glyceryl tricaprylate; glyceryl tricaprate; glyceryl triundecanoate; glyceryl trilaurate; glyceryl trioleate; glyceryl trilinoleate; glyceryl trilinolenate;
glyceryl tricaprylate/caprate; glyceryl tricaprylate/caprate/laurate; glyceryl tricaprylate/caprate/linoleate; glyceryl tricaprylate/caprate/stearate;
saturated polyglycolized glycerides; linoleic glycerides; caprylic/capric glycerides may be used. In addition, a mixture of surfactants and/or oils and/or alcohols may be used.
[0059] In some einbodiments of the present invention, the selected lipophilic xenobiotic is mixed with an alkanol and a suitable nonionic surfactant before addition to an actively growing microbial culture. If the parent coinpound is mixed with an alcohol, the alcohol may be ethanol.
Additional suitable alcohols include: methanol, isopropanol, 1-propanol, and other suitable alcohols well known in the art.
Solvents [0060] In some embodiments of the present invention, the xenobiotic coinpound is mixed with a solvent before being added to a microorganism culture. The solvents may be sterilized prior to mixing with the xenobiotic compound. Optionally, a surfactant is also added to the xenobiotic compound - solvent mixture. Suitable solvents of the present invention may be any solvent that does not inhibit the growth and metabolism of the microorganism. The solvent may be non-polar, polar aprotic, or polar protic. For example, the solvents include the hydrocarbon series solvents, such as benzene, toluene, n-hexane, cyclohexane, etc.; ether series solvents such as diethyl ether, tetrahydrofuran, 1,4-dioxane, methyl t-butyl ether, dimethoxyethane, ethylene glycol dimethyl ether, etc.; alcohols such as methanol, ethanol, 1-propanol, isopropanol, etc.;
halogen-containing solvents such as methylene chloride, chloroform, 1, 1, 1 -trichloroethane, etc.;
and other solvents such as dimethylformamide, N-methylpyrrolidone, hexamethylphosphorotriamide, etc. The solvent is preferably not DMSO.
[0061] The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of the present invention. While this invention is particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be inade therein without departing from the spirit and scope of the invention as defined by the appended claims.
EXAMPLES
[0062] In the examples below, the following abbreviations have the following meanings.
Abbreviations not defined have their generally accepted meanings.
C = degree Celsius hr = hour min = minute sec or s= second M = micromolar mM = millimolar M = molar ml = milliliter l = microliter mg = milligram g = microgratn mol = mole pmol = picomole ATCC = American Type Culture Collection PBS = phosphate buffered saline CSA = cyclosporin A
TDM = therapeutic dose monitoring LC = liquid chromatography MS = mass spectrometry PEG = polyethylene glycol General Material and Methods Liquid Chrofnatographic (LC) Conditions [0063] For Liquid Chromatography (LC or HPLC) a column having a stationary phase formed by chemically bonding a long-chain hydrocarbon group to a porous silica matrix, a Waters Symmetry C8, 2.1X50mm, 3.5 m analytical column (Waters cat# WAT 200624) with a guard column 2 x 20mm (Upchurch Scientific cat# C-130B) packed with Perisorb RP-8 (Upchurch Scientific cat# C-601) was used. The solvent percentages and flow rates utilized in the LC
program are given in Table 2:
0.2 % GAA +
10-5M Na Acetate MeOH:MtBE (9:1) Flow rate Time (min) (%) (%) (mL/min) 0.00 55 45 0.5 5.00 45 55 0.5 10.00 5 95 0.5 12.00 5 95 0.5 12.01 55 45 0.5 15.00 55 45 0.5 Mass Spectral (MS) Conditions [0064] For Mass Spectroscopy, an Applied Biosystems / MDS Sciex API3000 (Analyst software v 1.2) machine was used. Run time was 15 minutes, injection volume was 5 L, Guard Column Temperature and Analytical Column Temperatures were 60 C. Manual settings were as follows:
Turbo Ion Spray was 8000, Turbo Ion Spray horizontal setting was positive 4, Turbo Ion Spray lateral setting was 10. The Sciex machine was set with the parameters shown in Table 3.
Table 3 MS Settings MS Settings:
Scan type: MRM (Multiple Reaction Monitoring) Polarity: Positive Period Duration 15.00 min Period Cycle: 1.32 sec # of Cycles: 692 Advanced MS Settings:
Resolution Q1: Low Q3: Low Intensity threshold: 0 Settling time: 50 msec Pause time: 30 msec Parameter Settings:
Ion Source: Turbo ion spray Nebulizer Gas: 12 Curtain Gas: 8 Collision Gas: 12 Ion Spray voltage: 5000 V
Temperature: 550 C
Compound Settings:
Declustering Potential: 60 V
Focusing Potential: 400 V
Collision Energy: 90 V
Table 4 shows ions and ion-specific instrument settings.
Q1 Mass (amu) Q3 Mass (ainu) Time (msec) 1222.8 1098.7 100 1236.8 1112.7 100 1252.8 1128.7 100 1252.8 1224.7 100 1270.8 1112.7 100 1254..8 1130.7 100 1268.8 1128.7 100 1268.8 1144.7 100 1238.8 1114.7 100 1268.8 1240.8 100 Example 1 Preparation of ISA247 metabolites from whole blood [0065] Whole blood was taken from humans after administration of ISA247 (a 50:50 mixture of cis:tr=ans ISA247). ISA247 and its metabolites were extracted from whole blood using tertbutyl-methyl-ether (or methyl tertbutyl ether, MTBE), dried and reconstituted into metilanol.
2mL of MTBE (cat. No. 7001-2; Caledon) were added to 200 uL of blood, shaken for 10 minutes, and spun down in a table top centrifuge for 2 minutes. The top MTBE
layer was removed and concentrated under vacuum. That residue was reconstituted in 200 uL of methanol.
Bile and urine extractions can be performed similarly, as can extractions from microsome preparations and biotransformation preparations. Once extracted, metabolites can be characterized using HPLC-MS, NMR, or other techniques known in the art. Figure 3 shows that results of LC-MS performed as described in General Materials and Methods. The metabolites from whole blood include three main groups, the diols, hydroxylated and demethylated metabolites.
Example 2 ISA247 Metabolite Production by a Dog Liver Microsome Preparation Preparation of Dog Microsomes [0066] Dog liver microsomes were prepared in the following manner: after removing the liver, it was flushed with 1.15% potassium chloride (KC1); diced into small pieces (approximately 25 g) and ground until major chunks were disintegrated in chilled grinding buffer (0.1 M phosphate buffer pH 7.4; 4 C; 1:1 ratio of buffer to liver) utilizing a Polytron Homogenizer at 15,000 rpm for 3 to 5 minutes, thus forming a homogenate, which contained membrane-bounded organelles, including liver microsomes. After decantation of supernatant from the particulate matter, the supernatant was centrifuged for 90 min. at 100,000 x g to yield a pellet and a supernatant.
Protein content was determined using the Lowry protein assay. The protein concentration of this microsomal preparation was approximately 23.2 mg/mL. To avoid enzyme activity loss, microsomes were stored in 4.0 or 6.0 mL aliquots at -80 C to avoid freeze thaw cycling.
[0067] The following ingredients were added stepwise into a 257 mL Erlenmeyer flask: 57.3 mg of NADP, 254 mg of Glucose-6-Phosphate, and 23.0 mg NADPH were added to 6.0 mL of Phosphate Buffer (adjusted to pH 7.4). Then, 2.0 mL of 5.0 mM MgCI, and 6.0 mL
Glucose-6-Phosphate Dehydrogenase (10 units/mL, available from CALBIOCHEM, San Diege, CA, Cat.
No. 346774) were added to the solution. Finally, 10 mL of Phosphate Buffer (pH
7.4) was added. A 6mL volume of dog liver microsoine, prepared as above, was added into the flask, followed by ISA247, and incubated at 37 C for 2 hours at 250 rpm in an environmentally controlled incubator/shaker. At 2 hours, the reaction was stopped by adding 500 L of 2M HCI.
[0068] Metabolites produced by this method were then extracted with an organic solvent, and further separated using high-pressure liquid chromatography (HPLC). The metabolites were further characterized by electrospray mass spectrometry (MS) and NMR. The resulting metabolite profile (data not shown) was similar to that from human whole blood. However, the diols from the dog microsome were inuch less abundant.
Example 3 ISA247 Metabolite Production by Biotransformation using Saccharopolyspora erytliraea [0069] This example illustrates a biotransforination system utilized microorganisins containing the microbial equivalent of human cytochrome P450 microsomal enzyme and a mediuin suitable for active growth of the microorganism. The parent compound, which is poorly soluble in water, was mixed with ethanol and a surfactant prior to addition to the biotransforination system. In this exainple, ISA247 in ethanol was mixed with TWEEN 40 and then added to a biotransformation system containing Saccharopolyspora erytheraea (ATCC 11635).
[0070] Starting cultures were prepared as follows. Fifteen tubes (16 x 26 mm;
6 ml each) of the ISP2 medium slants were prepared containing 4 g/L yeast extract, 10g/L
malt extract, 4g/L
dextrose and 2g/L agar. These ingredients were mixed in demineralized water up to liter, pH
neutralized as needed to 7 with NaOH. The medium was sterilized for 30 min. at 100 C. The tubes were stored at 4 C until use. Each slant was inoculated with Saccharopolyspora erythraea (ATCC number 11635). Innoculated slants were grown for three weeks under sterile conditions at room temperature.
[0071] Precultures were transferred to Phase I Media. Phase I Media were prepared with 10 g/L dextrin, 1 g/L glucose, 3 g/L beef extract, 10 g/L yeast extract, 5 g/L
magnesium sulfate and 400 mg/L potassium phosphate. These ingredients were mixed in deionized water up to 1 liter, pH neutralized as needed to 7 with NaOH and 50 mL was aliquoted into each of two baffled 250 mL culture flasks. The medium was sterilized for 30 min. at 100 C. 5 mL of the media was aliquoted into a slant tube containing Sacchar~opolyspora ef ythraea. The cells were scraped off the surface of the slant and 2.5 mL of the suspension was placed in each flask. The flasks were placed on a Labline Incubator at 27 C and shaken at 250 rpm for 3 days (72 hrs).
[0072] Saccharopolyspora erythraea was transferred to Phase II media from Phase I media by centrifuging the contents of a Phase I flask at 3300 rpm for 5 min. and decanting off the supernatant to obtain a pellet. 5 mL of Phase II media was added to the pellet and the tube was vortexed, then centrifuged at 3300 rpm for 4 min. Again the supernatant was decanted. The pellet was resuspended in Phase II media. The subsequent suspension was added to 50 mL of Phase II medium in a baffled culture flask.
[0073] Phase II Media contained 10 g/L glucose, 1 g/L yeast extract, 1 g/L
beef extract and 11.6 g/L of 3-N-morpholinopropanesulfonic acid (MOPS) buffer. These ingredients were mixed in deionized water to one liter; then 50 mL were dispensed into two baffled culture flasks (250 mL). After adjustment to pH to 7.0 with 5M NaOH, the medium was autoclaved for 30 min. at 100 C, then cooled. TWEEN 40 was autoclaved before mixing with ISA247 and ethanol.
[0074] ISA247 (4mg of -50150 mixture of E and Z isomers) was dissolved in 95%
ethanol (0.1 ml), then mixed with 0.4 ml TWEEN 40 (polyoxyethylene sorbitan monopalmitate;
Cat. No.
P1504. Sigma-Aldrich, St. Louis, MO) The parent compound-surfactant mixture was then added to Saccharopolyspora efythYaea in the Phase II culture medium. A zero time sample was obtained and frozen. Each flask was then capped and placed on an Innova Incubator at 27 C and incubated for 120 hrs with shaking at 170 rpm.
[0075] A second sample was obtained from the Phase II culture medium. The zero time sample and the second sample were extracted using tert-butyl-methyl ether (cat. No. 7001-2;
Caledon). The extracted metabolites were reconstituted in methanol (HPLC
grade) and analyzed by LC-MS as previously described. As shown in Figure 4, the metabolite profile obtained by this method is similar to that obtained from human whole blood (see Example 1). When the biotransformation mixture was analyzed, seven metabolite compounds were found to be present:
IM4n (ISA247 Metabolite that is N-demethylated at amino acid-4), IM9 (ISA247 Metabolite that is hydroxylated at amino acid-9), IM4 (ISA247 Metabolite that is hydroxylated at amino acid-4), IM1-c-1(See table 1), IMl-d-1 (Table 1), IM1-d-2 (Table 1) and IM1-d-3 (Table 1). Therefore, seven out of eight ISA247 metabolites revealed in human blood were produced in this biotransformation systein.
Effect of Varying the Surfactant in Biotransformation using Saccharopolyspora erythraea [0076] To test the effects of different surfactants, actively growing Phase II
cultures of Sacchar opolyspora erythraea (ATCC number 11635) were prepared as above. Seven tubes each containing ISA247 (56 mg; 50/50 mixture of E- and Z-isomers) in ethanol (0.33 ml) were prepared. A surfactant (0.67 ml/tube) was added to each tube as follows:
Tube 1 - PEG 400 (polyethylene glycol 400; Carbowax - Fisher Scientific, FairLonn NJ);
Tube 2 - castor oil (Wiler Fine Chemicals Ltd, London Ont.);
Tube 3 - isopropyl myristate (Wiler Fine Chemicals Ltd, London Ont.);
Tube 4- glycerine (BDH Fine Chemicals, Toronto Ont. Lot # 120343/73865);
Tube 5- Cremophor EL (Sigma Chemical, St Louis MO);
Tube 6 - Labrasol (Gatte Fosse, Cedex France); and, Tube 7- TWEEN 40 (Aldrich Chemical Company Inc., Milwaukee Wis.).
[0077] The parent compound-surfactant mixture was added to the actively growing culture of Saccharopolyspora and a zero time sample was taken. After incubation with shaking at 27 C for days, samples were obtained, extracted, and the metabolites were quantified as described in Example 4. Area under the curve of HPLC peaks, similar to those shown in Figures 3 and 4, was 5 measured as an indication of the quantity of metabolite present. The HPLC
peaks corresponded to one N-demethylated metabolite, which was identified as IM4n; two hydroxylated metabolites which were identified as IM4 and IM9; one cyclic metabolite identified as IM 1-c-1; and three diol metabolites, diols formed at the 1 amino acid of the ISA247 compound, identified as IMl-d-1, IM1-d-2 and IM1-d-3 (See Table 1). The seven surfactants were not all equivalent in their activity in increasing the production of metabolites in the biotransformation preparation. As shown in Figure 5, the addition of glycerine or PEG 400 to the biotransformation preparation resulted in significant increases in the quantity of metabolites produced.
However, the addition of castor oil, isopropyl myristate, CremophorRO, Labrasol and TWEEN 40 all resulted in an increase in the production of metabolites in the biotransformation preparation, over the production of metabolites in the preparation without surfactant (not shown).
Biotransformation Using Various Microorganisms [0078] A variety of microorganisms were evaluated for production of ISA247 metabolites from ISA247, including Curvularia lunata (University of Alberta Microfungal Collection and Herbarium (UAMH) 9191; ATCC 12017), Cunninghamella echinulata var. elegans (UAMH
7370; ATCC 36112), Curvularia echinulata var. blakesleena (UAMH 8718; ATCC
8688a), Cunninghamella echinulata var. elegans (UAMH 7369; ATCC 26269), Beauvaria bassiana (UAMH 8717; ATCC 7159), Actinomycetes (ATCC 53828), Actinoplanes sp. (ATCC
53771), CunnitzghaJnella echinulata (UAMH 4144; ATCC 36190), Cunninghamella echinulata (UAMH
7368; ATCC 9246), Cunninglaamella bainiere (echinulata) (UAMH 4145; ATCC 9244) and Saccharopolyspora eiythraea (ATCC 11635).
[0079] These microorganisms were screened for metabolite conversion yield (amount of known ISA247 metabolites produced) as well as metabolic diversity (number of different ISA247 metabolites produced). The microorganisms were grown in Phase I and incubated with ISA247 in Phase II. After the addition of ISA247 to the fermentation media, samples were taken from the media and analyzed with LC-MS against a huinan standard ISA247 metabolite profile to identify and quantify the metabolites collected. After primary testing of each strain via 96 hour biotransformation cycles, the two strains with the highest combination of metabolite conversion and metabolic diversity were tested again in Phase III with different media compositions, in order to select improved media compositions.
Phase I/Phase II methods [0080] Each microorganism tested was maintained on culture-specific agar slants. All slants were prepared one month in advance to avoid contamination. Prepared agar media were autoclaved at 123 C and partial pressure of 360 mmHg for 58 minutes, cooled slightly, and 6 mL
was pipetted into sterile 16x125 mm culture tubes. After placing the agar into the tube, the tube was rested on an incline to create a slant, cooled until the agar set, labeled, and incubated at 27 C
for 1-2 weeks. ATCC 11635 and ATCC 53771 were sporulated using ISP agar (0.4%
yeast extract, 1% malt extract, 0.4% dextrose and 2% granulated agar). ATCC 53828, and UAMH 8718 were sporulated using potato dextrose agar (PDA, 3.9% in distilled water).
UAMH 4145, UAMH 7369, UAMH 7370 and UAMH 9191 were sporulated on cereal slants (10%% mixed cereal, dry, preferably pabulum for infants; 2% granulated agar;
the cereal was mixed before and after sterilization to prevent clumping of the cereal and inadequate distribution of agar in the slants). Following incubation for two weeks, each microorganism was inoculated onto the microorganism-specific agar and returned to 27 C. Once a full lawn of colonies was seen on the slants, the slants were preferably used immediately in Phase I or, if necessary, stored at 4 C.
[0051] Subsequently, 2mL of sterile Phase I media Phase I media (containing ISP seed broth:
1% dextrin, 1% glucose, 0.27% beef extract, 1% yeast extract, 0.004% magnesium sulfate, and 0.036% potassium diphosphate, at pH 7.0) was added to a source slant containing the ' microorganism to be tested. Using a sterile inoculating loop, the colonies were removed, vortexed and then the resulting suspension was added to 50 mL of sterile Phase I media, contained in a sterile, 250-mL baffled culture flask. Each flask was incubated for 96 hours in to increase biomass before the addition of ISA247 in Phase II.
[0082] To prepare biomass for transfer to Phase II, the cells were washed thoroughly to remove Phase I residue. Phase I contents were aseptically transferred into a 50-mL conical centrifuge tube, centrifuged at 3300 rpm for five minutes, and decanted to remove supematant.
The cells were washed with 5mL of excess Phase II media (3.65% MOPS, 0.31%
yeast extract, 3.14% glucose and 0.31% beef extract, at pH 7.0) and centrifuged again for five minutes at 3300 rpm, after which the supernatant was decanted and 5mL of fresh Phase II media was added. The resulting mixture was vortexed thoroughly and quantitatively transferred under aseptic conditions to 50 mL of sterile Phase II media in a 250mL baffled culture flask. A portion of ISA247 (0.5 mL, 56 mg/mL of ISA247 that was predominantly in trans forin in 33.75% ethanol (95%):66.25% glycerol) was added to the media and the mixture was shaken vigorously. Sample aliquots were taken (0.5mL, 12 hour increments over 96 hours of Phase II
fermentation) and stored at -80 C until LC-MS analysis. Fermentation was concluded after 96 hours.
Phase III
[0083] In Phase ITI, ATCC 53771 and ATCC 11635 strains were incubated for 96 hours in Media C (2% glucose, 2% starch, 0.5% yeast extract, 2% soybean protein, 0.32%
CaCO3, 0.25%
NaCI) as seed broth and then aseptically transferred in separate replicate trials to either Media 3 (2% glycerol, 0.5% peptone, 0.5% yeast extract, 0.2% beef extract, 0.1%
(NH4)2HP04, 0.1%
CaCO3, 0.3% NaCl, 0.03% MgSO4-7H2O, at pH 7.0) or Media 16 (2% glucose, 1%
glycerin, 1%
peptone, 1% meat extract, 2% soybean protein, 0.5% CaCO3, 0.5% NaCI, at pH
7.0). Care was exercised when taking samples for LC-MS due to the viscous-consistency of the fennentation media. -Table 5: Summary of the media and agar used in Example 5 ATCC ATCC ATCC UAMH UAMH UAMH UAMH UAMH UAMH
Media ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP2 Media 3 Media 3 ATCC ATCC ATCC UAMH UAMH UAMH UAMH UAMH UAMH
Media Media Agar ISP ISP PDA CER CER CER PDA PDA CER
Metabolite analysis by LC-MS
[0084] Samples were thawed from storage at -80 C and 16x10 mm culture tubes were labeled to represent the samples to be analyzed. A 200 L aliquot was removed from each 0.5 mL
sample, and 25uL of a 1 mg/mL solution of CsA (Cyclosporine A) was added as an internal standard. 2mL of HPLC-grade methanol was added to each sample and the samples were capped and shaken for twenty minutes. The samples were centrifuged at 3300 rpm for lminute and 45seconds. The supematant was decanted into clean, labeled 16x10 mm culture tubes and vacuum concentrated to remove organic solvent. The dried layer, containing botli the metabolites and parent drug was re-constituted in 200 L of HPLC-grade methanol, and the samples were quantitatively transferred to auto sampler vials. Samples were run for 15 minutes in deionized water with 0.01 % acetic acid/sodium acetate, starting with a 12 minute gradient of increasing m-TBE (methyl tert-butyl ether) and HPLC grade methanol.
[0085] Figure 6 is a graph of mass spec signal versus retention time for typical metabolites from a sample pooled from human participants. Table 6 summarizes the ion masses found, corresponding quantifiable ISA247 metabolites and approximate retention times.
Ion masses quantified included 1223, 1237, 1239, 1253, 1255, 1267 and 1271. Note that two diols (IM1-d-1 and IMl-d-4) were detected here, whereas three diols (IM1-d-1, IM1-d-2, and IMl-d-3) were detected in Example.1. The reason for this discrepancy is that the trans-form of ISA247 is metabolized to IM1-d-1 and IM1-d-4, while the cis-form of ISA247 is metabolized to IMl-d-2 and IM1-d-3. Since the parent compound used in Example 1 was a 50:50 mixture of cis:trans, and the parent compound in this Example was predominantly trans-ISA247, the metabolite profiles were different with respect to the diols.
Table 6 Ion Mass Metabolite from ISA247 Approximate Retention Time (min) 1223 IM4n 9.789 1237 ISA247 10.206 1239 1239 8.340 1253 IM1-c-1 ; IM9; IM4 8.575;8.939;9.440 1255 1255 8.899 1267 CSA(Internal Standard) 10.678 1271 IM1-d-1; IM1-d-4 7.535; 8.166 [0086] The relative % conversion was calculated from the ratio of the area under the curve (AUC) of the peak for each quantifiable metabolite detected and the area under the curve of the Internal CsA standard using the following equation:
% Conversion = (Metabolite AUC)/ (CsA Intennal Standard AUC) x 100 Results [0087] The metabolic diversity after 96 hours of biotransformation is summarized in Table 7.
A check mark indicates a quantifiable amount of metabolite was produced. Table 8 lists the amount of each metabolite produced in each microorganism tested.
Table 7 Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
IM1-d-1 IM1-cl-4 IM4n IM1-c-1 Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
Rank 1 st 4th 3rd 9th 8th 7th 6th 5th 2nd Table 8(All weights in nanograms) Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
IM1-d-1 1120.3 <1.00 <1.00 <1.00 <1.00 <1.00 0.00 <1.00 13.96 IM 1-d-4 4.38 0.00 0.00 0.00 0.00 0.00 2.65 0.00 1.11 1239 6.38 <1.00 <1.00 <1.00 <1.00 <1.00 9.42 <1.00 2.44 1255 23.11 0.00 <1.00 0.00 0.00 0.00 <1.00 0.00 0.00 IM4n 22.02 <1.00 20.99 1.51 0.00 0.00 0.00 <1.00 7.01 IM1-c-1 71.80 <1.00 3.175 <1.00 <1.00 <1.00 0.00 <1.00 6.78 1M9 63.22 <1.00 0.00 <1.00 <1.00 <1.00 0.00 <1.00 11.69 IM4 35.40 <1.00 0.00 1.18 0.00 <1.00 0.00 <1.00 1.66 [0088] Thus, ainong the microorganisms examined in this experiment, ATCC 11635 displayed the greatest percent conversion and the greatest metabolic diversity. Eight known human ISA247 metabolites were detected in ATCC 11635 sainples. UAMH 4145 produced six of the eight metabolites. ATCC 53771, often used in the lab because of its inherent ability to generate large amounts of IM4n (6.66%), produces five of the eight human metabolites.
produced four of the eight metabolites; although each of these metabolites was produced in small quantities, the rare metabolite 1239 was produced. UAMH 7369 and UAMH 7370 each produced four of the metabolites. UAMH 9191 and UAMH 8718 each produced six metabolites. UAMH 8717 produced three metabolites.
[0089] Another factor considered in microorganism selection was the presence of "rare"
metabolites of ISA247. "Rare" is defined as metabolites that are not produced in large amounts by ATCC 11635, e.g., IM1-d-4, 1239 and 1255. IM1-d-4 was present in ATCC
11635, UAMH
8717 and UAMH 9191, but was produced in the greatest quantity by ATCC 11635.
The microbial strains ATCC 11635, ATCC 53771, ATCC 53828, UAMH 7370, UAMH 8717, UAMH 8718, UAMH 9191 all produced 1239. The microorganism that produced the greatest quantity was UAMH 8717. The metabolite corresponding to ion 1255 was manufactured by ATCC 11635, UAMH 4145, ATCC 53771, UAMH 8717, with the greatest conversion by ATCC
11635.
[0090] In Phase III of this experiment, ATCC 11635 and ATCC 53771 were cultured in Media 3 and Media 16, and the effects of the media compared. Figure 7 shows the results for ATCC
11635. Media 3 and Media 16 produced similar amounts of each metabolite except for IM1-d-1, IM 1-d-4 and IM 1-c-1. IM 1-d-1 production decreased with Media 3 and was not present in detectable levels with Media 16. IM1-d-4 production decreased with both Media 3 and Media 16. IM1-c-1 production increased 10% with Media 3. Figure 8 is a graph of the effect of media composition on the production of ISA247 metabolites in ATCC 53771. IM1-d-1 was detected only when using ISP2 media and IM9 and IM4 were only detected when using Media 3 and Media 16. Most of the metabolites, with the exception of IM1-d-4 were increased in quantity by using Media 3 and Media 16. Therefore, the growth media of the microorganisms can be altered to optimize the effect of biotransformation.
Effect of surfactants and solvents in biotransformation using Beauvaria bassiana [0091] In Example 5, Beauvaria bassiana (UAMH 8717) only weakly produced metabolites. To test if different surfactants or solvents can change the production profile, dimethyl sulfoxide (DMSO) and TWEEN 40 were coinpared to glycerol (used in Example 5).
0.5 mL of a 56 mg/mL ISA247 solution (in 33.75% ethanol (95%):66.25% DMSO or TWEEN
40 instead of glycerol) was added into 50 mL of media. The same Phase I and Phase II media and procedure of Example were followed.
[0092] As shown in Figure 9, the use of glycerol as a surfactant led to the formation of IMl-d-4, 1239, and 1255; DMSO led to the formation of IM1-d-1, IM4n and IM4; and resulted in IMl-d-1, IM1-d-4, 1255, IM4n, IM9 and IM4. The ainount of conversion was also dramatically changed. Consequently, biotransformation results can be optimized by changing the solvents or surfactants used to deliver the parent compound, and a skilled artisan can choose a certain solvent, surfactant and media to increase the production of a given metabolite of combination of metabolites.
[0093] All of the publications, patents and patent applications cited in this application are herein incorporated by reference in their entirety to the same extent as if the disclosure of each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.
[0094] A number of einbodiments of the invention have been described.
Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.
Turbo Ion Spray was 8000, Turbo Ion Spray horizontal setting was positive 4, Turbo Ion Spray lateral setting was 10. The Sciex machine was set with the parameters shown in Table 3.
Table 3 MS Settings MS Settings:
Scan type: MRM (Multiple Reaction Monitoring) Polarity: Positive Period Duration 15.00 min Period Cycle: 1.32 sec # of Cycles: 692 Advanced MS Settings:
Resolution Q1: Low Q3: Low Intensity threshold: 0 Settling time: 50 msec Pause time: 30 msec Parameter Settings:
Ion Source: Turbo ion spray Nebulizer Gas: 12 Curtain Gas: 8 Collision Gas: 12 Ion Spray voltage: 5000 V
Temperature: 550 C
Compound Settings:
Declustering Potential: 60 V
Focusing Potential: 400 V
Collision Energy: 90 V
Table 4 shows ions and ion-specific instrument settings.
Q1 Mass (amu) Q3 Mass (ainu) Time (msec) 1222.8 1098.7 100 1236.8 1112.7 100 1252.8 1128.7 100 1252.8 1224.7 100 1270.8 1112.7 100 1254..8 1130.7 100 1268.8 1128.7 100 1268.8 1144.7 100 1238.8 1114.7 100 1268.8 1240.8 100 Example 1 Preparation of ISA247 metabolites from whole blood [0065] Whole blood was taken from humans after administration of ISA247 (a 50:50 mixture of cis:tr=ans ISA247). ISA247 and its metabolites were extracted from whole blood using tertbutyl-methyl-ether (or methyl tertbutyl ether, MTBE), dried and reconstituted into metilanol.
2mL of MTBE (cat. No. 7001-2; Caledon) were added to 200 uL of blood, shaken for 10 minutes, and spun down in a table top centrifuge for 2 minutes. The top MTBE
layer was removed and concentrated under vacuum. That residue was reconstituted in 200 uL of methanol.
Bile and urine extractions can be performed similarly, as can extractions from microsome preparations and biotransformation preparations. Once extracted, metabolites can be characterized using HPLC-MS, NMR, or other techniques known in the art. Figure 3 shows that results of LC-MS performed as described in General Materials and Methods. The metabolites from whole blood include three main groups, the diols, hydroxylated and demethylated metabolites.
Example 2 ISA247 Metabolite Production by a Dog Liver Microsome Preparation Preparation of Dog Microsomes [0066] Dog liver microsomes were prepared in the following manner: after removing the liver, it was flushed with 1.15% potassium chloride (KC1); diced into small pieces (approximately 25 g) and ground until major chunks were disintegrated in chilled grinding buffer (0.1 M phosphate buffer pH 7.4; 4 C; 1:1 ratio of buffer to liver) utilizing a Polytron Homogenizer at 15,000 rpm for 3 to 5 minutes, thus forming a homogenate, which contained membrane-bounded organelles, including liver microsomes. After decantation of supernatant from the particulate matter, the supernatant was centrifuged for 90 min. at 100,000 x g to yield a pellet and a supernatant.
Protein content was determined using the Lowry protein assay. The protein concentration of this microsomal preparation was approximately 23.2 mg/mL. To avoid enzyme activity loss, microsomes were stored in 4.0 or 6.0 mL aliquots at -80 C to avoid freeze thaw cycling.
[0067] The following ingredients were added stepwise into a 257 mL Erlenmeyer flask: 57.3 mg of NADP, 254 mg of Glucose-6-Phosphate, and 23.0 mg NADPH were added to 6.0 mL of Phosphate Buffer (adjusted to pH 7.4). Then, 2.0 mL of 5.0 mM MgCI, and 6.0 mL
Glucose-6-Phosphate Dehydrogenase (10 units/mL, available from CALBIOCHEM, San Diege, CA, Cat.
No. 346774) were added to the solution. Finally, 10 mL of Phosphate Buffer (pH
7.4) was added. A 6mL volume of dog liver microsoine, prepared as above, was added into the flask, followed by ISA247, and incubated at 37 C for 2 hours at 250 rpm in an environmentally controlled incubator/shaker. At 2 hours, the reaction was stopped by adding 500 L of 2M HCI.
[0068] Metabolites produced by this method were then extracted with an organic solvent, and further separated using high-pressure liquid chromatography (HPLC). The metabolites were further characterized by electrospray mass spectrometry (MS) and NMR. The resulting metabolite profile (data not shown) was similar to that from human whole blood. However, the diols from the dog microsome were inuch less abundant.
Example 3 ISA247 Metabolite Production by Biotransformation using Saccharopolyspora erytliraea [0069] This example illustrates a biotransforination system utilized microorganisins containing the microbial equivalent of human cytochrome P450 microsomal enzyme and a mediuin suitable for active growth of the microorganism. The parent compound, which is poorly soluble in water, was mixed with ethanol and a surfactant prior to addition to the biotransforination system. In this exainple, ISA247 in ethanol was mixed with TWEEN 40 and then added to a biotransformation system containing Saccharopolyspora erytheraea (ATCC 11635).
[0070] Starting cultures were prepared as follows. Fifteen tubes (16 x 26 mm;
6 ml each) of the ISP2 medium slants were prepared containing 4 g/L yeast extract, 10g/L
malt extract, 4g/L
dextrose and 2g/L agar. These ingredients were mixed in demineralized water up to liter, pH
neutralized as needed to 7 with NaOH. The medium was sterilized for 30 min. at 100 C. The tubes were stored at 4 C until use. Each slant was inoculated with Saccharopolyspora erythraea (ATCC number 11635). Innoculated slants were grown for three weeks under sterile conditions at room temperature.
[0071] Precultures were transferred to Phase I Media. Phase I Media were prepared with 10 g/L dextrin, 1 g/L glucose, 3 g/L beef extract, 10 g/L yeast extract, 5 g/L
magnesium sulfate and 400 mg/L potassium phosphate. These ingredients were mixed in deionized water up to 1 liter, pH neutralized as needed to 7 with NaOH and 50 mL was aliquoted into each of two baffled 250 mL culture flasks. The medium was sterilized for 30 min. at 100 C. 5 mL of the media was aliquoted into a slant tube containing Sacchar~opolyspora ef ythraea. The cells were scraped off the surface of the slant and 2.5 mL of the suspension was placed in each flask. The flasks were placed on a Labline Incubator at 27 C and shaken at 250 rpm for 3 days (72 hrs).
[0072] Saccharopolyspora erythraea was transferred to Phase II media from Phase I media by centrifuging the contents of a Phase I flask at 3300 rpm for 5 min. and decanting off the supernatant to obtain a pellet. 5 mL of Phase II media was added to the pellet and the tube was vortexed, then centrifuged at 3300 rpm for 4 min. Again the supernatant was decanted. The pellet was resuspended in Phase II media. The subsequent suspension was added to 50 mL of Phase II medium in a baffled culture flask.
[0073] Phase II Media contained 10 g/L glucose, 1 g/L yeast extract, 1 g/L
beef extract and 11.6 g/L of 3-N-morpholinopropanesulfonic acid (MOPS) buffer. These ingredients were mixed in deionized water to one liter; then 50 mL were dispensed into two baffled culture flasks (250 mL). After adjustment to pH to 7.0 with 5M NaOH, the medium was autoclaved for 30 min. at 100 C, then cooled. TWEEN 40 was autoclaved before mixing with ISA247 and ethanol.
[0074] ISA247 (4mg of -50150 mixture of E and Z isomers) was dissolved in 95%
ethanol (0.1 ml), then mixed with 0.4 ml TWEEN 40 (polyoxyethylene sorbitan monopalmitate;
Cat. No.
P1504. Sigma-Aldrich, St. Louis, MO) The parent compound-surfactant mixture was then added to Saccharopolyspora efythYaea in the Phase II culture medium. A zero time sample was obtained and frozen. Each flask was then capped and placed on an Innova Incubator at 27 C and incubated for 120 hrs with shaking at 170 rpm.
[0075] A second sample was obtained from the Phase II culture medium. The zero time sample and the second sample were extracted using tert-butyl-methyl ether (cat. No. 7001-2;
Caledon). The extracted metabolites were reconstituted in methanol (HPLC
grade) and analyzed by LC-MS as previously described. As shown in Figure 4, the metabolite profile obtained by this method is similar to that obtained from human whole blood (see Example 1). When the biotransformation mixture was analyzed, seven metabolite compounds were found to be present:
IM4n (ISA247 Metabolite that is N-demethylated at amino acid-4), IM9 (ISA247 Metabolite that is hydroxylated at amino acid-9), IM4 (ISA247 Metabolite that is hydroxylated at amino acid-4), IM1-c-1(See table 1), IMl-d-1 (Table 1), IM1-d-2 (Table 1) and IM1-d-3 (Table 1). Therefore, seven out of eight ISA247 metabolites revealed in human blood were produced in this biotransformation systein.
Effect of Varying the Surfactant in Biotransformation using Saccharopolyspora erythraea [0076] To test the effects of different surfactants, actively growing Phase II
cultures of Sacchar opolyspora erythraea (ATCC number 11635) were prepared as above. Seven tubes each containing ISA247 (56 mg; 50/50 mixture of E- and Z-isomers) in ethanol (0.33 ml) were prepared. A surfactant (0.67 ml/tube) was added to each tube as follows:
Tube 1 - PEG 400 (polyethylene glycol 400; Carbowax - Fisher Scientific, FairLonn NJ);
Tube 2 - castor oil (Wiler Fine Chemicals Ltd, London Ont.);
Tube 3 - isopropyl myristate (Wiler Fine Chemicals Ltd, London Ont.);
Tube 4- glycerine (BDH Fine Chemicals, Toronto Ont. Lot # 120343/73865);
Tube 5- Cremophor EL (Sigma Chemical, St Louis MO);
Tube 6 - Labrasol (Gatte Fosse, Cedex France); and, Tube 7- TWEEN 40 (Aldrich Chemical Company Inc., Milwaukee Wis.).
[0077] The parent compound-surfactant mixture was added to the actively growing culture of Saccharopolyspora and a zero time sample was taken. After incubation with shaking at 27 C for days, samples were obtained, extracted, and the metabolites were quantified as described in Example 4. Area under the curve of HPLC peaks, similar to those shown in Figures 3 and 4, was 5 measured as an indication of the quantity of metabolite present. The HPLC
peaks corresponded to one N-demethylated metabolite, which was identified as IM4n; two hydroxylated metabolites which were identified as IM4 and IM9; one cyclic metabolite identified as IM 1-c-1; and three diol metabolites, diols formed at the 1 amino acid of the ISA247 compound, identified as IMl-d-1, IM1-d-2 and IM1-d-3 (See Table 1). The seven surfactants were not all equivalent in their activity in increasing the production of metabolites in the biotransformation preparation. As shown in Figure 5, the addition of glycerine or PEG 400 to the biotransformation preparation resulted in significant increases in the quantity of metabolites produced.
However, the addition of castor oil, isopropyl myristate, CremophorRO, Labrasol and TWEEN 40 all resulted in an increase in the production of metabolites in the biotransformation preparation, over the production of metabolites in the preparation without surfactant (not shown).
Biotransformation Using Various Microorganisms [0078] A variety of microorganisms were evaluated for production of ISA247 metabolites from ISA247, including Curvularia lunata (University of Alberta Microfungal Collection and Herbarium (UAMH) 9191; ATCC 12017), Cunninghamella echinulata var. elegans (UAMH
7370; ATCC 36112), Curvularia echinulata var. blakesleena (UAMH 8718; ATCC
8688a), Cunninghamella echinulata var. elegans (UAMH 7369; ATCC 26269), Beauvaria bassiana (UAMH 8717; ATCC 7159), Actinomycetes (ATCC 53828), Actinoplanes sp. (ATCC
53771), CunnitzghaJnella echinulata (UAMH 4144; ATCC 36190), Cunninghamella echinulata (UAMH
7368; ATCC 9246), Cunninglaamella bainiere (echinulata) (UAMH 4145; ATCC 9244) and Saccharopolyspora eiythraea (ATCC 11635).
[0079] These microorganisms were screened for metabolite conversion yield (amount of known ISA247 metabolites produced) as well as metabolic diversity (number of different ISA247 metabolites produced). The microorganisms were grown in Phase I and incubated with ISA247 in Phase II. After the addition of ISA247 to the fermentation media, samples were taken from the media and analyzed with LC-MS against a huinan standard ISA247 metabolite profile to identify and quantify the metabolites collected. After primary testing of each strain via 96 hour biotransformation cycles, the two strains with the highest combination of metabolite conversion and metabolic diversity were tested again in Phase III with different media compositions, in order to select improved media compositions.
Phase I/Phase II methods [0080] Each microorganism tested was maintained on culture-specific agar slants. All slants were prepared one month in advance to avoid contamination. Prepared agar media were autoclaved at 123 C and partial pressure of 360 mmHg for 58 minutes, cooled slightly, and 6 mL
was pipetted into sterile 16x125 mm culture tubes. After placing the agar into the tube, the tube was rested on an incline to create a slant, cooled until the agar set, labeled, and incubated at 27 C
for 1-2 weeks. ATCC 11635 and ATCC 53771 were sporulated using ISP agar (0.4%
yeast extract, 1% malt extract, 0.4% dextrose and 2% granulated agar). ATCC 53828, and UAMH 8718 were sporulated using potato dextrose agar (PDA, 3.9% in distilled water).
UAMH 4145, UAMH 7369, UAMH 7370 and UAMH 9191 were sporulated on cereal slants (10%% mixed cereal, dry, preferably pabulum for infants; 2% granulated agar;
the cereal was mixed before and after sterilization to prevent clumping of the cereal and inadequate distribution of agar in the slants). Following incubation for two weeks, each microorganism was inoculated onto the microorganism-specific agar and returned to 27 C. Once a full lawn of colonies was seen on the slants, the slants were preferably used immediately in Phase I or, if necessary, stored at 4 C.
[0051] Subsequently, 2mL of sterile Phase I media Phase I media (containing ISP seed broth:
1% dextrin, 1% glucose, 0.27% beef extract, 1% yeast extract, 0.004% magnesium sulfate, and 0.036% potassium diphosphate, at pH 7.0) was added to a source slant containing the ' microorganism to be tested. Using a sterile inoculating loop, the colonies were removed, vortexed and then the resulting suspension was added to 50 mL of sterile Phase I media, contained in a sterile, 250-mL baffled culture flask. Each flask was incubated for 96 hours in to increase biomass before the addition of ISA247 in Phase II.
[0082] To prepare biomass for transfer to Phase II, the cells were washed thoroughly to remove Phase I residue. Phase I contents were aseptically transferred into a 50-mL conical centrifuge tube, centrifuged at 3300 rpm for five minutes, and decanted to remove supematant.
The cells were washed with 5mL of excess Phase II media (3.65% MOPS, 0.31%
yeast extract, 3.14% glucose and 0.31% beef extract, at pH 7.0) and centrifuged again for five minutes at 3300 rpm, after which the supernatant was decanted and 5mL of fresh Phase II media was added. The resulting mixture was vortexed thoroughly and quantitatively transferred under aseptic conditions to 50 mL of sterile Phase II media in a 250mL baffled culture flask. A portion of ISA247 (0.5 mL, 56 mg/mL of ISA247 that was predominantly in trans forin in 33.75% ethanol (95%):66.25% glycerol) was added to the media and the mixture was shaken vigorously. Sample aliquots were taken (0.5mL, 12 hour increments over 96 hours of Phase II
fermentation) and stored at -80 C until LC-MS analysis. Fermentation was concluded after 96 hours.
Phase III
[0083] In Phase ITI, ATCC 53771 and ATCC 11635 strains were incubated for 96 hours in Media C (2% glucose, 2% starch, 0.5% yeast extract, 2% soybean protein, 0.32%
CaCO3, 0.25%
NaCI) as seed broth and then aseptically transferred in separate replicate trials to either Media 3 (2% glycerol, 0.5% peptone, 0.5% yeast extract, 0.2% beef extract, 0.1%
(NH4)2HP04, 0.1%
CaCO3, 0.3% NaCl, 0.03% MgSO4-7H2O, at pH 7.0) or Media 16 (2% glucose, 1%
glycerin, 1%
peptone, 1% meat extract, 2% soybean protein, 0.5% CaCO3, 0.5% NaCI, at pH
7.0). Care was exercised when taking samples for LC-MS due to the viscous-consistency of the fennentation media. -Table 5: Summary of the media and agar used in Example 5 ATCC ATCC ATCC UAMH UAMH UAMH UAMH UAMH UAMH
Media ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP 2 ISP2 Media 3 Media 3 ATCC ATCC ATCC UAMH UAMH UAMH UAMH UAMH UAMH
Media Media Agar ISP ISP PDA CER CER CER PDA PDA CER
Metabolite analysis by LC-MS
[0084] Samples were thawed from storage at -80 C and 16x10 mm culture tubes were labeled to represent the samples to be analyzed. A 200 L aliquot was removed from each 0.5 mL
sample, and 25uL of a 1 mg/mL solution of CsA (Cyclosporine A) was added as an internal standard. 2mL of HPLC-grade methanol was added to each sample and the samples were capped and shaken for twenty minutes. The samples were centrifuged at 3300 rpm for lminute and 45seconds. The supematant was decanted into clean, labeled 16x10 mm culture tubes and vacuum concentrated to remove organic solvent. The dried layer, containing botli the metabolites and parent drug was re-constituted in 200 L of HPLC-grade methanol, and the samples were quantitatively transferred to auto sampler vials. Samples were run for 15 minutes in deionized water with 0.01 % acetic acid/sodium acetate, starting with a 12 minute gradient of increasing m-TBE (methyl tert-butyl ether) and HPLC grade methanol.
[0085] Figure 6 is a graph of mass spec signal versus retention time for typical metabolites from a sample pooled from human participants. Table 6 summarizes the ion masses found, corresponding quantifiable ISA247 metabolites and approximate retention times.
Ion masses quantified included 1223, 1237, 1239, 1253, 1255, 1267 and 1271. Note that two diols (IM1-d-1 and IMl-d-4) were detected here, whereas three diols (IM1-d-1, IM1-d-2, and IMl-d-3) were detected in Example.1. The reason for this discrepancy is that the trans-form of ISA247 is metabolized to IM1-d-1 and IM1-d-4, while the cis-form of ISA247 is metabolized to IMl-d-2 and IM1-d-3. Since the parent compound used in Example 1 was a 50:50 mixture of cis:trans, and the parent compound in this Example was predominantly trans-ISA247, the metabolite profiles were different with respect to the diols.
Table 6 Ion Mass Metabolite from ISA247 Approximate Retention Time (min) 1223 IM4n 9.789 1237 ISA247 10.206 1239 1239 8.340 1253 IM1-c-1 ; IM9; IM4 8.575;8.939;9.440 1255 1255 8.899 1267 CSA(Internal Standard) 10.678 1271 IM1-d-1; IM1-d-4 7.535; 8.166 [0086] The relative % conversion was calculated from the ratio of the area under the curve (AUC) of the peak for each quantifiable metabolite detected and the area under the curve of the Internal CsA standard using the following equation:
% Conversion = (Metabolite AUC)/ (CsA Intennal Standard AUC) x 100 Results [0087] The metabolic diversity after 96 hours of biotransformation is summarized in Table 7.
A check mark indicates a quantifiable amount of metabolite was produced. Table 8 lists the amount of each metabolite produced in each microorganism tested.
Table 7 Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
IM1-d-1 IM1-cl-4 IM4n IM1-c-1 Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
Rank 1 st 4th 3rd 9th 8th 7th 6th 5th 2nd Table 8(All weights in nanograms) Metabolite ATCC UAMH ATCC ATCC UAMH UAMH UAMH UAMH UAMH
IM1-d-1 1120.3 <1.00 <1.00 <1.00 <1.00 <1.00 0.00 <1.00 13.96 IM 1-d-4 4.38 0.00 0.00 0.00 0.00 0.00 2.65 0.00 1.11 1239 6.38 <1.00 <1.00 <1.00 <1.00 <1.00 9.42 <1.00 2.44 1255 23.11 0.00 <1.00 0.00 0.00 0.00 <1.00 0.00 0.00 IM4n 22.02 <1.00 20.99 1.51 0.00 0.00 0.00 <1.00 7.01 IM1-c-1 71.80 <1.00 3.175 <1.00 <1.00 <1.00 0.00 <1.00 6.78 1M9 63.22 <1.00 0.00 <1.00 <1.00 <1.00 0.00 <1.00 11.69 IM4 35.40 <1.00 0.00 1.18 0.00 <1.00 0.00 <1.00 1.66 [0088] Thus, ainong the microorganisms examined in this experiment, ATCC 11635 displayed the greatest percent conversion and the greatest metabolic diversity. Eight known human ISA247 metabolites were detected in ATCC 11635 sainples. UAMH 4145 produced six of the eight metabolites. ATCC 53771, often used in the lab because of its inherent ability to generate large amounts of IM4n (6.66%), produces five of the eight human metabolites.
produced four of the eight metabolites; although each of these metabolites was produced in small quantities, the rare metabolite 1239 was produced. UAMH 7369 and UAMH 7370 each produced four of the metabolites. UAMH 9191 and UAMH 8718 each produced six metabolites. UAMH 8717 produced three metabolites.
[0089] Another factor considered in microorganism selection was the presence of "rare"
metabolites of ISA247. "Rare" is defined as metabolites that are not produced in large amounts by ATCC 11635, e.g., IM1-d-4, 1239 and 1255. IM1-d-4 was present in ATCC
11635, UAMH
8717 and UAMH 9191, but was produced in the greatest quantity by ATCC 11635.
The microbial strains ATCC 11635, ATCC 53771, ATCC 53828, UAMH 7370, UAMH 8717, UAMH 8718, UAMH 9191 all produced 1239. The microorganism that produced the greatest quantity was UAMH 8717. The metabolite corresponding to ion 1255 was manufactured by ATCC 11635, UAMH 4145, ATCC 53771, UAMH 8717, with the greatest conversion by ATCC
11635.
[0090] In Phase III of this experiment, ATCC 11635 and ATCC 53771 were cultured in Media 3 and Media 16, and the effects of the media compared. Figure 7 shows the results for ATCC
11635. Media 3 and Media 16 produced similar amounts of each metabolite except for IM1-d-1, IM 1-d-4 and IM 1-c-1. IM 1-d-1 production decreased with Media 3 and was not present in detectable levels with Media 16. IM1-d-4 production decreased with both Media 3 and Media 16. IM1-c-1 production increased 10% with Media 3. Figure 8 is a graph of the effect of media composition on the production of ISA247 metabolites in ATCC 53771. IM1-d-1 was detected only when using ISP2 media and IM9 and IM4 were only detected when using Media 3 and Media 16. Most of the metabolites, with the exception of IM1-d-4 were increased in quantity by using Media 3 and Media 16. Therefore, the growth media of the microorganisms can be altered to optimize the effect of biotransformation.
Effect of surfactants and solvents in biotransformation using Beauvaria bassiana [0091] In Example 5, Beauvaria bassiana (UAMH 8717) only weakly produced metabolites. To test if different surfactants or solvents can change the production profile, dimethyl sulfoxide (DMSO) and TWEEN 40 were coinpared to glycerol (used in Example 5).
0.5 mL of a 56 mg/mL ISA247 solution (in 33.75% ethanol (95%):66.25% DMSO or TWEEN
40 instead of glycerol) was added into 50 mL of media. The same Phase I and Phase II media and procedure of Example were followed.
[0092] As shown in Figure 9, the use of glycerol as a surfactant led to the formation of IMl-d-4, 1239, and 1255; DMSO led to the formation of IM1-d-1, IM4n and IM4; and resulted in IMl-d-1, IM1-d-4, 1255, IM4n, IM9 and IM4. The ainount of conversion was also dramatically changed. Consequently, biotransformation results can be optimized by changing the solvents or surfactants used to deliver the parent compound, and a skilled artisan can choose a certain solvent, surfactant and media to increase the production of a given metabolite of combination of metabolites.
[0093] All of the publications, patents and patent applications cited in this application are herein incorporated by reference in their entirety to the same extent as if the disclosure of each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.
[0094] A number of einbodiments of the invention have been described.
Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.
Claims (18)
1. A method for producing at least one metabolite of a xenobiotic compound in a microorganism, comprising the steps of:
(a) providing a mixture of the xenobiotic compound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and (c) incubating the culture for a period of time sufficient to allow the metabolite to form.
(a) providing a mixture of the xenobiotic compound and a surfactant;
(b) adding the mixture to a culture of the microorganism; and (c) incubating the culture for a period of time sufficient to allow the metabolite to form.
2. The method of claim 1 wherein the mixture comprises the xenobiotic compound, a solvent, and the surfactant.
3. The method of claim 2 wherein the solvent is an alcohol.
4. The method of claim 3 wherein the alcohol is ethanol.
5. The method of any one of claims 1-4 wherein the solvent comprises both an alcohol and DMSO.
6. The method of any one of claims 1-5 wherein the microorganism is selected from the group consisting of Actinoplanes sp., Streptomyces griseus, Streptomyces setonii, and Saccharopolyspora erthyraea.
7. The method of any one of claims 1-5 wherein the microorganism is Cunningham ellaechinulata.
8. The method of any one of claims 1-5 wherein the microorganism is Nerospora crassa.
9. The method of any one of claims 1-5 wherein the microorganism is Actinoplanes sp.
10. The method of any one of claims 1-9 wherein the surfactant is selected from the group consisting of PEG 400, castor oil, isopropyl myristate, glycerine, cremophor®, Labrasol®, and TWEEN® 40.
11. The method of any one of claims 1-10 wherein said xenobiotic compound is selected from the group consisting of immunosuppressants and anti-bacterial compounds.
12. The method of any one of claims 1-11 wherein the xenobiotic compound is a cyclosporin compound.
13. The method of claim 12 wherein the cyclosporin compound is ISA247.
14. The method of claim 12 wherein the cyclosporin compound is cyclosporin A.
15. The method of any one of claims 1-14, wherein the metabolite is selected from the group consisting of IM1-d-1, IM1-d-2, IM1-d-3, IM1-d-4, IM1-c-1, IM1-c-2, IM1-e-1, IM1-e-2, IM1-e-3, IM9, IM4, IM4n, IM6, IM46, IM69, and IM49.
16. The method of any one of claims 1-15 wherein the microorganism is Saccharopolyspora erthyraea (ATCC 11635).
17. The method of any one of claims 1-16 further comprising the step of isolating the metabolite from the culture.
18. A method for identifying a microorganism suitable for use in a biotransformation system comprising: a) comparing the structure of a compound to be metabolized with a known enzyme activity; b) identifying an enzyme that expresses the known enzyme activity;
c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyme in a biotransformation system to make metabolites of the compound.
c) identifying a microorganism that expresses the identified enzyme; and d) using the microorganism that expresses the identified enzyme in a biotransformation system to make metabolites of the compound.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63884104P | 2004-12-23 | 2004-12-23 | |
US60/638,841 | 2004-12-23 | ||
PCT/CA2005/001972 WO2006066416A1 (en) | 2004-12-23 | 2005-12-23 | Method for biotransformation of the clyclosporin compound isa247 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2591781A1 true CA2591781A1 (en) | 2006-06-29 |
Family
ID=36601332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002591781A Abandoned CA2591781A1 (en) | 2004-12-23 | 2005-12-23 | Method for biotransformation of the clyclosporin compound isa247 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1831389A1 (en) |
JP (1) | JP2008524992A (en) |
KR (1) | KR20070101867A (en) |
AU (1) | AU2005318844A1 (en) |
CA (1) | CA2591781A1 (en) |
WO (1) | WO2006066416A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
EP2197461B1 (en) * | 2007-10-08 | 2018-02-21 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors |
JP5526379B2 (en) * | 2009-06-25 | 2014-06-18 | 独立行政法人製品評価技術基盤機構 | Identification of new compounds |
IT201600103929A1 (en) | 2016-10-17 | 2018-04-17 | Ferrari Spa | BRAKING SYSTEM FOR A ROAD VEHICLE WITH FORCED RECIRCULATION OF THE BRAKE FLUID |
BR112019013234A2 (en) * | 2017-01-05 | 2020-02-11 | National Institute Of Advanced Industrial Science And Technology | GENE INVOLVED IN THE SYNTHESIS OF CYCLIC PEPTIDE COMPOUND, METHOD FOR THE PRODUCTION OF CYCLIC PEPTIDE COMPOUND USING THE SAME, AND TRANSFORMING UNDERSTANDING THE SAME |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
WO2021219465A1 (en) * | 2020-04-27 | 2021-11-04 | Basf Se | A fermentation medium and method for eryhromycin fermentation production |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI108730B (en) * | 1999-11-19 | 2002-03-15 | Valio Oy | Process for Preparation of Conjugated Linoleic Acid |
CN1246451C (en) * | 2003-08-07 | 2006-03-22 | 上海来益生物药物研究开发中心有限责任公司 | Application of cloud point system in biotransformation |
-
2005
- 2005-12-23 WO PCT/CA2005/001972 patent/WO2006066416A1/en active Application Filing
- 2005-12-23 EP EP05823812A patent/EP1831389A1/en not_active Withdrawn
- 2005-12-23 KR KR1020077016868A patent/KR20070101867A/en not_active Application Discontinuation
- 2005-12-23 AU AU2005318844A patent/AU2005318844A1/en not_active Abandoned
- 2005-12-23 CA CA002591781A patent/CA2591781A1/en not_active Abandoned
- 2005-12-23 JP JP2007547128A patent/JP2008524992A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20070101867A (en) | 2007-10-17 |
WO2006066416A1 (en) | 2006-06-29 |
AU2005318844A1 (en) | 2006-06-29 |
JP2008524992A (en) | 2008-07-17 |
EP1831389A1 (en) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2591781A1 (en) | Method for biotransformation of the clyclosporin compound isa247 | |
RU2387657C2 (en) | Regiospecific synthesis of rapamycin 42-ester derivatives | |
Murthy et al. | Cyclosporin-A production by Tolypocladium inflatum using solid state fermentation | |
Oskay | Effects of some Environmental Conditions on Biomass and Antimicrobial Metabolite Production by Streptomyces Sp., KGG32. | |
KR101663234B1 (en) | Cyclic peptide from nonomuraea sp., process for the production thereof, and pharmaceutical composition for the prevention or treatment of mycobacteria related disease comprising the same | |
CN1267332A (en) | Method for producing polyketides | |
ES2348865T3 (en) | ACTINOSYNNEMA PRETIOSUM MUTANT STRAIN WITH INCREASED MAITANSINOID PRODUCTION. | |
HU217683B (en) | A process for producing cyclosporin a and a novel microbial species to be employed therein | |
AU2003238752A1 (en) | Mutant actinosynnema pretiosum strain with increased maytansinoid production | |
CA2016082A1 (en) | New fk-520 microbial transformation product | |
Vorob'ev et al. | Methylovirgula ligni gen. nov., sp. nov., an obligately acidophilic, facultatively methylotrophic bacterium with a highly divergent mxaF gene | |
Bernardi et al. | Secondary metabolites of endophytic actinomycetes: Isolation, synthesis, biosynthesis, and biological activities | |
Bouras et al. | Effect of amino acids containing sulfur on dithiolopyrrolone antibiotic productions by Saccharothrix algeriensis NRRL B‐24137 | |
CA2257254C (en) | Antibiotic producing microbe | |
Ghisalberti | Anti-infective agents produced by the Hyphomycetes genera Trichoderma and Gliocladium | |
Gajzlerska et al. | Use of three-carbon chain compounds as biosynthesis precursors to enhance tacrolimus production in Streptomyces tsukubaensis | |
Ismaiel | Production of the immunosuppressant cyclosporin A by a new soil isolate, Aspergillus fumigatus, in submerged culture | |
WO2006011156A1 (en) | Process for producing tacrolimus (fk - 506) using vegetable oil as sole source of carbon | |
Ohta et al. | Production of human metabolites of cyclosporin A, AM1, AM4N and AM9, by microbial conversion | |
Ismaiel et al. | Some optimal culture conditions for production of cyclosporin a by Fusarium roseum | |
Řeháček et al. | The biochemistry of cyclosporin formation: a review | |
CN101397540A (en) | Culture medium for producing staurosporine and method thereof | |
CN113234629B (en) | Streptomyces cmx-10-19 strain capable of producing natamycin by fermentation and application thereof | |
CA2018710A1 (en) | L-683,590 microbial transformation product | |
RU2495937C1 (en) | Method of preparation of tacrolimus by microbiological synthesis method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |